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Abstract 
 
   The increasing incidence of metabolic disorders, like insulin resistance, type 2 
diabetes (T2D), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), obesity and 
metabolic syndrome (MS), has reached epidemic proportions. Knowing that life 
expectancy is increasing worldwide and that ageing is associated with a high prevalence 
of these disorders, it is crucial to stop this epidemic.  
   The carotid bodies (CB) are peripheral chemoreceptors, classically defined as O2 
sensors, also implicated in energy homeostasis. Our previous work showed in young 
animals submitted to 25 weeks of hypercaloric diets that the abolition of the CB activity 
restored the insulin sensitivity and glucose tolerance. Knowing that age is associated 
with the development of insulin resistance, the general aim of this work was to 
investigate the impact of long-term hypercaloric diet consumption and the abolishment 
of CB activity, through the CB sensitive nerve resection, the carotid sinus nerve (CSN) 
on glucose homeostasis in older rats. Also, knowing that NAFLD is one of the core 
comorbidities associated with dysmetabolism, we have focus on liver metabolism. Aged 
rats were fed with high-fat high-sucrose (HFHSu) diet for 44 weeks and after this period 
half was submitted to CSN resection and the other to a sham surgery. Animals were 
followed-up during 9 weeks for insulin sensitivity, glucose tolerance, fasting plasma 
glucose, weight and fat variation. After a terminal experiment lipid profile, liver lipid 
content and hepatocellular analysis were assessed. Abolishment of the CB/CSN activity 
in old rats reduced weight gain, restored insulin sensitivity and glucose tolerance, 
decreased plasma triglycerides and had beneficial impact on liver function.  
   Concluding, this study demonstrated for the first time that the modulation of the CB 
activity might be a potential therapeutic intervention in age-induced and diet 
exacerbated metabolic dysfunctions, as well in liver-associated metabolic dysfunction in 
young and old animals.  
 
Key words: Aging, carotid body, carotid sinus nerve resection, dyslipidemia, insulin 
resistance, liver, metabolic diseases, non-alcoholic fatty liver disease, sympathetic 
nervous system, type 2 diabetes.  
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Resumo  
 
   A crescente incidência de distúrbios metabólicos, como resistência à insulina, diabetes 
tipo 2 (T2D), dislipidemia, doença hepática gordurosa não alcoólica (NAFLD), 
obesidade e síndrome metabólica (SM), atingiu proporções epidêmicas. A expectativa 
de vida está a aumentar mundialmente e o envelhecimento está associado a uma alta 
prevalência desses distúrbios, sendo crucial parar esta epidemia. 
   Os corpos carotídeos (CB) são quimiorreceptores periféricos, classicamente definidos 
como sensores de O2 implicados na homeostase energética. Trabalhos anteriores 
mostraram em animais jovens com 25 semanas de dietas hipercalóricas, que a abolição 
da atividade do CB restaurava a sensibilidade à insulina e a tolerância à glucose. 
Sabendo que a idade contribui para a resistência à insulina, o objetivo geral deste 
trabalho foi investigar em ratos velhos o impacto de dietas hipercalóricas perlongadas e 
abolição da atividade do CB, através da ressecção do nervo do seio carotídeo (CSN) na 
homeostase da glucose. Sabendo que a NAFLD é uma das principais comorbidades 
associadas ao dismetabolismo, focamos no metabolismo hepático. Ratos idosos foram 
alimentados com dieta hipercalórica (HFHSu) por 44 semanas, após esse período, 
metade foi submetido à ressecção do CSN e a outra à cirurgia sham. Os animais foram 
acompanhados durante 9 semanas, avaliando-se a sensibilidade à insulina, tolerância à 
glucose, glicemia em jejum, variação de peso e gordura. Após o procedimento terminal 
o perfil lipídico, conteúdo lipídico hepático e análise hepatocelular foram avaliados. A 
abolição da atividade CB/CSN em ratos idosos reduziu o ganho de peso, restaurou a 
sensibilidade à insulina e a tolerância à glucose, diminuiu os triglicerídeos plasmáticos e 
teve um impacto benéfico na função hepática. 
   Concluindo, este estudo demonstrou pela primeira vez que a modulação da atividade 
do CB pode ser uma potencial intervenção terapêutica em disfunções metabólicas 
induzidas pela idade, exacerbadas pela dieta, assim como dismetabolismo associado ao 
fígado em animais jovens e velhos. 
 
Palavras-chave: Envelhecimento, corpo carotídeo, ressecção do nervo carotídeo, 
resistência à insulina, fígado, doenças metabólicas, doença hepática gordurosa não 
alcoólica, sistema nervoso simpático, diabetes tipo 2. 
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 1 
1. Introduction 
1.1. Metabolic Diseases 
 
   Metabolic diseases are any type of disorder that disrupts the normal body metabolism, 
and comprises a broad spectrum going from congenital to acquired conditions (Enns, 
2019). Acquired metabolic diseases like obesity, type 2 diabetes (T2D), hypertension, 
insulin resistance, hyperglycemia, non-alcoholic fatty liver disease (NAFLD), 
hyperlipidemia and metabolic syndrome (MS) are the most common types and have 
reach an alarming incidence rate both in developed and developing countries (Heindel 
et al., 2017; Hossain, Kawar and Nahas, El, 2007; Hotamisligil, 2010). These metabolic 
diseases are considered multifactorial disorders intertwine with each other, with 
increasing prevalence and incidence (Kassi et al., 2011). Moreover, a systemic 
deterioration that resembles a longevity-related one is common in these metabolic 
diseases (Hotamisligil, 2010). 
 
1.2. Metabolic Syndrome  
 
   The MS is a cluster of complex disorders and is considered a major public-health 
epidemic, with increasing socioeconomic impact.(Alberti, Zimmet and Shaw, 2005) MS 
comprises a group of metabolic abnormalities that increase the risk of coronary heart 
disease, other forms of cardiovascular diseases, obesity and T2D (Grundy, 2004; Kassi 
et al., 2011). The MS’ main risk factors include: obesity, insulin resistance, raised 
fasting plasma glucose, hypertension and atherogenic dyslipidemia (elevated serum 
triglycerides (TG) and apolipoprotein B (apoB), increased small low-density 
lipoproteins (LDL), and reduced levels of high-density lipoprotein (HDL)) (Grundy, 
2016; Grundy et al., 2005; Kassi et al., 2011). Moreover, MS is also associated with 
other metabolic abnormalities, such as a chronic proinflammatory and prothrombotic 
state, NAFLD and obstructive sleep apnea (Kassi et al., 2011). 
   Named originally “Syndrome X” by Reaven (1988), was later renamed MS. Multiple 
definitions have been suggested throughout the years and because of that different 
definitions of the disease where used to identify patients (Mancia et al., 2010). Due to 
the multiplicity of definitions is very challenging to compare data from different studies 
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and to determine the prevalence of this epidemic disorder. Although, it is estimated that 
around 20-25% of the adults worldwide have MS, a number that continue to increase 
(Nolan et al., 2017). Data from the National Center for Health Statistics, estimates that 
in the US 1 in each 3 has MS (National Center for Health Statistics, 2012). 
 
   Initially, insulin resistance was suggested as the common and key pathological feature 
of MS, as it contributes to the development of T2D and cardiovascular diseases 
(Reaven, 1988). But now the MS’ definition was reviewed by several international 
organizations and expert groups and currently takes into account different parameters, 
such as, differences in population age, sex, genetic background, diet and physical 
activity (Alberti, Zimmet and Shaw, 2005; Devers, Campbell and Simmons, 2016; 
Krishnadath et al., 2016; Novak et al., 2013; Pan and Pratt, 2008). 
   The MS’ most widely used definitions are from the National Cholesterol Education 
Program: Adult Treatment Panel III (NCEP:ATPIII) and the International Diabetes 
Federation (IDF) (Table 1.1), that focus mainly on waist circumference, which is an 
alternative measure of central obesity. While, the definitions from World Health 
Organization (WHO), European Group for the study of Insulin Resistance (EGIR) and 
American Association of Clinical Endocrinology (AACE) focused on insulin resistance 
(Cornier et al., 2008; Kassi et al., 2011). Additionally, the American Heart 
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) states that the 
criteria to identify MS is based in the presence of three or more of the five risk factors 
(Grundy et al., 2005) (Table 1.1). 
   The MS, as stated before, is a term for a cluster of endogenous risk factors that 
increase the risk of developing other metabolic diseases, like T2D and obesity. MS can 
be seen as a vicious cycle that fuels itself, as its incidence increases with other 
metabolic diseases and its manifestation triggers other metabolic diseases as well as the 
prevalence of the previously established disorders (Girod and Brotman, 2003). The 
syndrome is not caused by a single factor but instead by an array of risk factors (Kassi 
et al., 2011). MS proves to be very heterogeneous in the population, as it can be 
clinically manifested in a variety of ways, especially among different racial and ethnic 
groups. Thus, making it very challenging to create guidelines for its definition (Mancia 
et al., 2010).  
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   Clinically, the first approach to manage MS is based on lifestyle interventions aiming 
to lower hypertension, fasting plasma glucose, atherogenic dyslipidemia, abdominal 
obesity and insulin resistance. Usually, lifestyle changes are difficult to implement or 
are not enough to manage MS and there is the need to introduce a pharmacological 
approach (Grundy et al., 2005; Thorp and Schlaich, 2015). Due to its multifactorial 
components and to its numbers and its increase additional research is needed to better 
understand the key pathological feature of MS. 
 
 
Table 1.1 - International Diabetes Federation (IDF) definition for Metabolic Syndrome 
(MS). 
For a person to be defined as having metabolic syndrome they must have: 
• Central obesity* 
• Plus any two of the following four factors: 
Raised Triglycerides 
≥ 150 mg/dl (1.7 mmol/l) 
or specific treatment for this lipid abnormality 
Reduced HDL 
Cholesterol 
< 40 mg/dl (1.03 mmol/l) in males 
< 50 mg/dl (1.29 mmol/l) in females 
or specific treatment for this lipid abnormality 
Raised blood 
Pressure (BP) 
Systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg 
or treatment of previously diagnosed hypertension 
Raised Fasting 
Plasma Glucose 
(FPG) 
FPG ≥ 100 mg/dl (5.6 mmol/l) 
or previously diagnosed T2D 
If above 100 mg/dl or 5.6 mmol/l, OGTT is strongly recommended 
but is not necessary to define presence of the syndrome. 
* Central obesity is defined as waist circumference with ethnicity specific values. If body mass 
index (BMI) is > 30 kg/m2, central obesity can be assumed and waist circumference does not 
need to be measured. In Europe, values for waist circumference are ≥ 94 cm in males and ≥ 80 
cm in females. OGTT – Oral Glucose Tolerance Test. 
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Figure 1. 1. Number of people with diabetes worldwide and per region in 2017 and 2045 
(20-79 years) (IDF, 2017). 
1.1.1. Type 2 Diabetes Mellitus 
 
   According to the American Diabetes Association and WHO, the classification of 
diabetes mellitus comprises four clinical classes: type 1 diabetes, T2D, gestational 
diabetes and other particular types of diabetes duo to other specific causes (Reviriego, 
2010; World Health Organization, 2006). The focus fall on the T2D as it is the most 
common type of diabetes, accounting for approximately 90% of all cases of the disease 
and considered the most common chronic diseases in the world (Bruno et al., 2005; 
Holman, Young and Gadsby, 2015). The high prevalence of this disease is associated 
with changes in lifestyle, leaning towards reduced physical activity, sedentarism and 
increasing rates of obesity (Shaw, Sicree and Zimmet, 2010).  
   According with IDF statistics it is believed that in 2017, 425 million people 
worldwide had diabetes, a number that is expected to continue to increase and by 2045, 
it is estimated that 629 million people will have diabetes (Figure 1.1) (International 
Diabetes Federation - Diabetes atlas (8th edition), 2017). Furthermore, in the 
Portuguese population, it is estimated that 34.5% of the population, between the ages of 
20-79 years, have diabetes or pre-diabetes and 44% of people with diabetes are unaware 
of their condition (Gardete-Correia et al., 2010).  
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   The early onset of this disease is called prediabetes and is characterized by a 
pancreatic β-cell dysfunction and a decrease in the insulin sensitivity, that starts before 
glucose changes are detectable (Tabák et al., 2012). The risk factors for prediabetes are 
the same as the ones for T2D and include: overweight, aging, poor diet and excess of 
calories, reduced physical activity, smoking and family history (Forouzanfar, Alexander 
and Anderson, 2015; Vazquez et al., 2007). However, people with prediabetes have a 
higher risk of developing T2D, yet not everyone with prediabetes will develop T2D.  
   Prediabetes is typically defined as blood glucose levels higher than normal, but bellow 
the diabetes diagnostic threshold for impaired glucose tolerance or impaired fasting 
glucose (Tabák et al., 2012) (Table 1.2 ). In contrast, T2D is defined by higher blood 
glucose levels ( ≥ 126 mg/dl), being characterized by an intolerance to glucose and 
impaired fasting glucose, and also by a defect in the insulin secretion (β-cell 
dysfunction) and insulin action (insulin resistance) (Table 1. 2). Also, T2D is 
accompanied by dysregulation of carbohydrates, lipid and protein metabolism 
(DeFronzo et al., 2015). Thus, the development of T2D from normal glucose tolerance 
to glucose intolerance and insulin resistance proves to be a continuous process, where 
several factors contribute to β-cell dysfunction, such as: aging, genetic abnormalities in 
incretin hormones (glucagon-like peptide 1 (GLP1) and gastric inhibitory polypeptide), 
lipotoxicity, glucotoxicity, reactive oxygen stress, hypersecretion of islet amyloid 
polypeptide and activation of inflammatory pathways (DeFronzo et al., 2015).  
   Taking into account all the T2D aspects, including the presence of defects in both 
insulin secretion (β-cell dysfunction) and insulin action, it is understandable the interest 
in the identification and implementation of interventions to prevent or delay the 
diseases’ onset (Kashyap and Defronzo, 2007). 
 
Table 1.2 –Glycemic reference values from the Associação Protectora dos Diabéticos de 
Portugal (APDP). 
Parameters Hypoglycemia Normal Prediabetes T2D 
Fasting Plasma 
Glucose 
< 70 mg/dl 70-100 mg/dl 100-126 mg/dl ≥ 126 mg/dl 
2 Hours Post-
prandial Glucose 
< 70 mg/dl 70-140 mg/dl 140-200 mg/dl ≥ 200 mg/dl 
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1.1.1.1. Insulin  
 
   Insulin is a peptide hormone, organized in two polypeptide chains, A and B, 
connected by disulphide bridges, essential in regulation of carbohydrate and fat 
metabolism in the body.  
   In order to exert its action on glucose metabolism, insulin is synthesized and release 
by pancreatic β-cells, into the bloodstream. In the insulin sensitive tissues, like skeletal 
muscle, liver and fat tissue, insulin binds to its specific receptor, the insulin receptor. 
When insulin binds to its receptor it initiates the uptake of glucose from the blood into 
the insulin-sensitive tissue, as skeletal muscle and fat tissue (Kahn and White, 1988; 
Saltiel and Kahn, 2001). In the liver, insulin stimulates glycogen production and blocks 
glucose production, increasing the fatty acids (FA) content in the tissue.  When the 
maximum capacity the FA in the liver is reached FA are released into the bloodstream 
and stored in the adipose tissue. Moreover, in the adipose tissue insulin inhibits the 
breakdown of TG into glycerol and FA (lipolysis) (Röder et al., 2016).  
   The insulin receptor, a tetrameric glycoprotein, from the subfamily of the tyrosine 
kinases receptors, consists of four subunits: two α-subunit entirely extracellular, 
containing the insulin-binding domain, and two transmembrane β-subunit, expressing 
insulin-stimulated kinase activity (Guo, 2014; Pessin and Saltiel, 2000; Saltiel and 
Kahn, 2001). The binding of insulin to the α-subunit of the insulin receptor leads to the 
dimerization and formation of the complex, α2β2 in the cell membrane and 
consequently the autophosphorylation of the β-subunit, thus activating the insulin 
receptor tyrosine kinase (Bajaj and DeFronzo, 2003) (Figure 1.2). This activation results 
in the phosphorylation of members of insulin receptor substrate (IRS) family, namely 
IRS1 and IRS2, Gap-1 and Shc (Bajaj and DeFronzo, 2003).  
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Figure 1. 2. Insulin signaling pathway. The increase in glucose levels stimulates the release of 
insulin from the pancreatic β-cells. Insulin binds to its insulin receptor, in insulin-sensitive 
tissues (adipose tissue and muscle), initiating a cascade of events that starts with 
phosphorylation of members of the insulin receptor substrate (IRS) family leading to the 
activation of phosphatidylinositol 3-kinase (PI3K), leading to the translocation of glucose 
transporter vesicles to the plasmatic membrane, thus enabling the uptake glucose. In the skeletal 
muscle and adipose tissue the glucose transporters are type 4 (GLUT4) (Saltiel and Kahn, 
2001).  
 
 
 
 
 
 
 
 
 
 
 
   The phosphorylated IRS1 and IRS2 proteins bind to a heterodimeric enzyme, 
phosphatidylinositol 3-kinase (PI3K), which is composed by a p85 regulatory subunit 
and a p110 catalytic subunit (Bajaj and DeFronzo, 2003). Once PI3K is activated, it 
initiates a signaling pathway that activates protein kinase B (PKB/AKT), leading to the 
translocation of glucose transporter type 4 (GLUT4) vesicles to the plasmatic 
membrane of muscle cells and adipocytes and to the activation of glycogen synthase 
(Hajduch, Litherland and Hundal, 2001; Saltiel and Kahn, 2001). In the liver, the major 
glucose transporter is the glucose transporter type 2 (GLUT2), located in the membrane 
of the hepatocytes and believed to be linked to the insulin receptor (Eisenberg et al., 
2005). GLUT2 can transport bi-directionally glucose but also other sugars, like, 
galactose, mannose, fructose and glucosamine (Colville et al., 1993; Karim, Adams and 
Lalor, 2012; Leturque, Brot-Laroche and Gall, Le, 2009; Zhao and Keating, 2007). In 
the fasting state, the liver produces glucose through glycogenolysis and 
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gluconeogenesis preceding to its release via GLUT2 (Karim, Adams and Lalor, 2012; 
Leturque, Brot-Laroche and Gall, Le, 2009). In the fed state, the rise of glucose and 
insulin levels inhibit hepatic glucose production, which leads to a decrease in GLUT2 
mediated release and the internalization of the hepatocyte GLUT2 and the insulin 
receptor together into endosomes (Karim, Adams and Lalor, 2012; Leturque, Brot-
Laroche and Gall, Le, 2009).  
   On the other hand, insulin also stimulates the mitogen-activated protein kinase 
(MAPK) signaling pathway through Grb2/Sos and ras, which is involved in gene 
expression, cell growth and differentiation (Cusi et al., 2000) (Figure 1.2). Also, MAPK 
is involved in the regulation of hepatic metabolism (Kyriakis and Avruch, 2001; Tang et 
al., 2014). In humans, the expression of p38δ MAPK has been shown to be increased in 
the liver of obese patients with NAFLD. So, MAPKs might drive hepatic metabolic 
dysfunction (Tang et al., 2014). Although this mechanism is not yet fully understood, 
p38-MAPK signaling, activated by oxidative stress, is thought to be associated with 
diminished insulin-dependent stimulation of insulin signaling and glucose transport 
activity (Lawan and Bennett, 2017).  
 
1.1.1.1.1. Insulin Signaling Defects in Type 2 Diabetes and Insulin 
Resistance 
 
   T2D is characterized by a defect on insulin action, where the insulin-sensitive tissues 
progressively loss the response to insulin, causing insulin resistance (Ye, 2013). Even 
though, the actual insulin resistance mechanisms remain unknown, several factors are 
linked with its manifestation, such as: obesity, inflammation, hyperinsulinemia, 
lipotoxicity /hyperlipidemia, stress, aging, fatty liver and hypoxia (Ye, 2013). The 
majority of these factors are deeply connected with obesity and aging, these making 
them the major risk factors for insulin resistance (Ye, 2013).  
   Although the insulin resistance mechanisms remain unclear the most expectable cause 
of its origin would be a downregulation of insulin receptors due to a generalized 
hyperinsulinemia, resulting from the increased insulin secretion from the beta cells 
(Grundy, 2016). This insulin overproduction leads to an increase in plasma insulin 
levels in fasting conditions. Independently of which appears first, hyperinsulinemia 
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appears to perpetuate the insulin resistance (Shanik et al., 2008). Some studies 
demonstrated a connection between insulin resistance and the downregulation of insulin 
receptors (Molina et al., 1989), others had shown that insulin binding to its receptors 
was normal in obese and lean diabetic individuals (Caro et al., 1987; Kashiwagi et al., 
1983). In light of these studies, another hypothesis for insulin resistance based on a 
possible defect on insulin signaling in T2D, through a reduction of the insulin-
stimulated tyrosine kinase activity, thus impairing the phosphorylation of IRS and 
activation of PI3K has emerged (Cusi et al., 2000; Krook et al., 2000; Saltiel and Kahn, 
2001). 
 
1.1.1.2. Glucose Homeostasis 
 
   Glucose is the main source of fuel for energy metabolism. Glucose homeostasis is 
ensured by a balance between glucose absorption from the intestine, glucose production 
by the liver and glucose uptake and metabolism by the peripheral tissues (Saltiel and 
Kahn, 2001).  
   The plasma glucose levels, in healthy people, are within the range of 4 and 7 mM, 
despite periods of fasting or feeding. After an overnight fast (10-12h), the majority of 
total glucose disposal takes place in the brain, which consumes around 50% of all 
glucose available. Approximately, 25% of glucose uptake takes place in the liver and 
gastrointestinal tissues. The remaining 25% is used mainly by the muscle, and in a 
lesser extent by the adipose tissue (DeFronzo, 2004). Additionally, the majority of 
glucose endogenous production is hepatic, approximately 85%, by glycogenolysis and 
gluconeogenesis. The kidneys contribute with 15% overall production (Gerich et al., 
2001; Magnusson et al., 1992).  
   After glucose ingestion (Figure 1.3), a peak in plasma glucose concentration 
stimulates insulin release by the pancreatic β-cells. The resultant hyperinsulinemia and 
hyperglycemia stimulate the uptake of glucose by the liver, skeletal muscle and adipose 
tissue (Arner, 2005; Röder et al., 2016). The influx of lipids into the adipose tissue 
leads to a decrease in lipolysis, with the inhibition of the TG hydrolysis into FA and 
glycerol (Arner, 2005). This inhibition leads to a decline in the plasma level of free fatty 
acids (FFA). Meanwhile, the uptake of glucose in the liver causes an inhibition of 
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Figure 1. 3. Insulin and glucagon effects on glucose homeostasis.  After food ingestion, the 
glucose levels increase, promoting the release of insulin from the pancreatic β-cells, which leads 
to the decrease in hepatic glucose production and the increase in muscle and adipose tissue 
glucose uptake. After an overnight fast, the blood glucose levels decrease, promoting the release 
of glucagon from the pancreatic α-cells, which leads to the hepatic glucose production, by 
increasing glycogenolysis and gluconeogenesis (adapted from Röder et al., 2016). 
↓ Blood Glucose
!-cells↑ Glycogenolysis↑ Gluconeogenesis
Normal Blood Glucose Levels
(4 - 6 mM)
β-cells
↑ Blood Glucose
↑ Glycogenesis
↓ Gluconeogenesis
↑ Glucose Uptake
Glucagon
Insulin
hepatic glucose production (gluconeogenesis) together with the increase in glycogen 
production (Bergman, 2000; Boden and Shulman, 2002; DeFronzo, 2004; Defronzo et 
al., 1985; Saltiel and Kahn, 2001). The glycogen production increases the FA content in 
the liver, which has a limited volume to store these lipids and when it can no longer 
hold the FA these are released into the bloodstream as FFA, that are later stored in the 
adipose tissue for posterior usage (Röder et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Glucagon also plays an important role in the glucose homeostasis regulation (Figure 
1.3). During fasting, approximately half of the total hepatic glucose output is dependent 
on the maintenance of normal basal glucagon levels (Cherrington, 1999). Whereas, after 
glucose ingestion, a-cell production of glucagon is inhibited contributing to the 
suppression of hepatic glucose production (DeFronzo, 2004). 
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   Plasma glucose levels are maintained within the normal range (4-6 mM) by the action 
of two hormones released by the pancreas: insulin, released by the β-cells and glucagon, 
released by a-cell. The balance of these hormones plays a vital role in the regulation of 
the glucose homeostasis (Röder et al., 2016). 
 
1.1.1.2.1. Glucose Homeostasis Defects in Type 2 Diabetes 
 
   In T2D, the insulin sensitive tissues, such as the muscle, liver and adipose tissue, are 
characterized by defects in insulin sensitivity. Consequently, in T2D patients, after 
glucose ingestion, an increase in hepatic glucose production occurs, even in the 
presence of high levels of plasma insulin, demonstrating an hepatic resistance to the 
insulin action (Firth et al., 1986). Studies have showed evidence that progression to 
glucose intolerance is associated with a prior development of insulin resistance (Figure 
1.4.) (DeFronzo, Bonadonna and Ferrannini, 1992). The progression to glucose 
intolerance results from a defect in the β-cell, as the cells cannot maintain its previously 
rate of insulin secretion in response to high values of glucose (DeFronzo, 2004). 
   In the adipose tissue, insulin can no longer fully inhibit lipolysis, leading to an 
increase in FFA levels, resulting in skeletal muscle and liver’s insulin resistance and 
impaired insulin secretion (Bajaj and DeFronzo, 2003; Boden and Chen, 1995; Kashyap 
et al., 2003). Hence, the increase in FFA ultimately leads to an increase in hepatic 
glucose production and impaired skeletal muscle’s glucose uptake (Boden et al., 2001; 
Roden et al., 1996). 
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Figure 1. 4. Natural history of type 2 diabetes. The prediabetic state of impaired glucose 
tolerance is characterized by increasing insulin resistance, compensatory hyperinsulinemia, 
and mild postprandial hyperglycemia. Here, the fasting blood glucose levels are maintained 
in near normal ranges. Also, macro and microvascular complications start to arise. The β-
cell then begins to fail, resulting in higher postprandial glucose levels and, with further loss 
of insulin secretory capacity and impaired glucorecognition, fasting blood glucose levels 
and hepatic glucose production increase (Ramlo-Halsted and Edelman, 1999). 
 
 
 
1.1.2. Non-Alcoholic Fatty Liver Disease 
 
   NAFLD is seen as the hepatic manifestation of the metabolic diseases, recognizing 
insulin resistance as a key factor in the genesis of the disease (Vanni et al., 2010). In 
contrast to the MS, the definition of NAFLD includes only one component: liver fat 
content > 5–10% per liver weight in the absence of excess alcohol consumption or any 
other liver disease (Vanni et al., 2010). Despite of having only one component, the 
pathogenesis of NAFLD can be influenced by several factors, such as, increases in 
dietary fat supply or even genetic factors (Vanni et al., 2010). 
   NAFLD compromises a broad disease spectrum from simple steatosis (non-alcoholic 
fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis (Kotronen et 
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Figure 1.5. Schematic progression of non-alcoholic fatty liver disease (NAFLD) and 
estimated prevalence of the disease stages (adapted from Alwahsh et al., 2016). 
Hepatocellular 
Cancer CirrhosisNASHNAFLD
Healthy 
Liver
al., 2007; Neuschwander-Tetri and Caldwell, 2003) (Figure 1.5). The early stage of the 
disease is characterized by a benign and reversible state of simple steatosis (fat 
accumulation). Whereas, NASH is defined by an irreversible hepatocyte injury, 
presence of inflammation and/or fibrosis which can progress into cirrhosis, liver failure 
and hepatocellular carcinoma (Vanni et al., 2010). 
 
 
 
 
 
 
 
   Approximately 10–25% of all patients with NAFLD develop NASH, although the 
evolution of steatosis to steatohepatitis remain unclarified (Day, 2005; Harrison, 
Torgerson and Hayashi, 2003). The “two-hits” model proposed by Day and James 
provide a pathophysiological foundation to the progression of liver damage, suggesting 
that the reversible deposition of TG (“first hit”) leads to metabolic and molecular 
alterations that sensitize the liver to the “second hit”, usually referred to as oxidative 
stress and cytokine-induced liver injury (Day and James, 1998). The liver is 
overwhelmed by the “second hit”, leading to the irreversible hepatocyte injury seen in 
NASH, like lipid peroxidation, induction of inflammatory cells and fibrogenesis with 
extracellular matrix deposition (Vanni et al., 2010). 
   NAFLD is a pathology that involves other organs besides the liver (Figure 1.6). For 
example, the muscle contributes to the pathology as when it becomes insulin resistant,  
glucose uptake in the muscle decreases and therefore the levels of circulating glucose 
are unable to decrease (Vanni et al., 2010; Yki-Järvinen, 1993). Whereas, the adipose 
tissue contributes with an increase in the FFA. The lipolysis is not adequately 
suppressed by insulin, which leads to an increased FFA content, the main source of 
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hepatic TG in NAFLD (Vanni et al., 2010; Yki-Järvinen, 1993). These factors together 
with liver´s overproduction of glucose, despite fasting hyperinsulinemia, contributes to 
the increase of fat deposition in the liver (Vanni et al., 2010; Yki-Järvinen, 1993). The 
progressive increase in hepatic fat (hepatosteatosis) that leads to NAFLD, contributes 
for the impaired ability of insulin to inhibit gluconeogenesis (Bugianesi et al., 2005; 
Seppälä-Lindroos et al., 2002). In fact, the hepatic insulin resistance increases the 
plasma glucose concentrations, stimulating insulin secretion and driving the vicious 
cycle of hyperinsulinemia and hyperglycemia (Juurinen et al., 2007; Vanni et al., 2010). 
   The liver is the major organ for lipid distribution. The hepatic ability to store fat is 
limited and the lipid excess can be oxidized, but it is mainly released as very low-
density lipoprotein (VLDL) (Kotronen et al., 2008; Taskinen, 2005; Vanni et al., 2010).   
So, after a meal, lipids are transported from the gut into the bloodstream in the form of 
chylomicrons (CM) and stored in the liver (Figure 1.6), where they are processed and 
assembled with apoB to form VLDL (Adiels et al., 2006, 2007; Fabbrini et al., 2008). 
One of insulin actions is to restrain VLDL production. However, in cases of hepatic 
insulin resistance, insulin is not able to inhibit VLDL production, leading to the 
overproduction of triglyceride-rich VLDL by the liver in the fasting state and during 
hyperinsulinemia (Adiels et al., 2006, 2007; Fabbrini et al., 2008; Lewis et al., 1993). 
Consequently, hepatic insulin resistance could lead to hypertriglyceridemia (Kotronen 
et al., 2008; Taskinen, 2005; Vanni et al., 2010). 
   Studies suggest that hepatic fat accumulation is involved in the pathogenesis of T2D 
and that hyperinsulinemia might be a consequence of NAFLD (Juurinen et al., 2007; 
Kotronen et al., 2008). Although, many studies search to better understand the key 
pathological feature of NAFLD, still no current therapies exist for NAFLD or NASH 
(Vanni et al., 2010). 
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1.1.3. Dyslipidemia 
 
   Dyslipidemia is strongly associated with metabolic diseases, like MS, T2D, obesity 
and NAFLD (Katsiki, Mikhailidis and Mantzoros, 2016; Klop, Elte and Cabezas, 2013; 
Mooradian, 2009). A core characteristic of dyslipidemia is insulin resistance, which 
influences the increase in FFA and the deregulation of the liver and adipose tissue lipid 
metabolism (Katsiki, Mikhailidis and Mantzoros, 2016). The erratic lipolysis in the 
adipose tissue leads to the release of FFA that are converted to TG in the liver, resulting 
in hypertriglyceridemia. This shows how metabolic diseases are connected to each 
other, through the disturbance of lipids metabolism in the body (Blaton, Korita and 
Bulo, 2008). 
Figure 1. 6. Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Different sources of 
fatty acids contribute to the development of fatty liver. Under conditions of insulin resistance, 
insulin does not adequately inhibit hormone-sensitive lipase (HSL), and lipolysis in white adipose 
tissue is not suppressed. Therefore, peripheral fats stored in adipose tissue flow to the liver by way 
of plasma free fatty acids (FFAs). Dietary fatty acids are also taken up by the liver through the 
uptake of intestinally derived chylomicron (CM). In addition, the combination of elevated plasma 
glucose (hyperglycemia) and insulin concentrations (hyperinsulinemia) promotes de novo fatty acid 
synthesis (lipogenesis) and impairs β-oxidation, thereby contributing to the development of hepatic 
steatosis. After the esterification step (conversion of fatty acids into triglycerides (TG)) TG can then 
be stored as lipid droplets within hepatocytes or secreted into the blood as very low-density 
lipoproteins (VLDL) (Postic et al., 2008). 
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Figure 1. 7. Role of insulin resistance in T2D dyslipidemia. Insulin resistant cells release 
FFA leading to an increased flux into the liver which promotes TG production and secretion of 
apolipoprotein B (ApoB) and VLDL. Cholesteryl ester transfer protein (CETP) promotes the 
exchange from VLDL-transported triglyceride to high-density lipoprotein (HDL)-transported 
cholerteryl ester (CE), which results in increased amounts of both atherogenic cholesterol-rich 
VLDL remnant particles and triglyceride-rich, cholesterol-depleted HDL particles (Feingold et 
al, 2000).   
   In insulin resistant patients, the increased supply of glucose (Figure 1.7.) results in an 
increase in FFA released from insulin-resistant adipocytes into bloodstream that are 
stored in the liver (Frayn, 2001; Mooradian, 2009; Taskinen, 2003). This efflux of FA 
into the liver elevates TG production leading to the increase of apoB and VLDL (Frayn, 
2001; Mooradian, 2009; Taskinen, 2003). The overproduction of VLDL drives the 
reciprocal exchange of FA: cholesterol-esters (CE) are transferred to VLDL and 
chylomicron remnants particles and TG are transferred to LDL particles, to form small-
dense LDL (SD LDL), and to HDL particles. These dense particles are well known for 
their high atherogenic potential (Blaton, Korita and Bulo, 2008; Frayn, 2001; 
Mooradian, 2009; Taskinen, 2003). The increased number of VLDL particles and TG 
drive the increase of SD LDL particles, that can promote a slight increase of LDL 
particles and a decrease HDL levels (Chatrath, Vuppalanchi and Chalasani, 2012; Klop, 
Elte and Cabezas, 2013; Mooradian et al., 2008; Mooradian, Haas and Wong, 2004; 
Wang and Peng, 2011).  
   In MS, similarly to obesity, cardiovascular disease (CVD), NAFLD and T2D, 
dyslipidemia is very commonly diagnosed, thus making it of vital importance in the 
vicious cycle of metabolic diseases (Chatrath, Vuppalanchi and Chalasani, 2012; 
Katsiki, Mikhailidis and Mantzoros, 2016; Manjunath et al., 2013). 
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1.3. Sympathetic Nervous System and Metabolic Dysfunction 
 
   The sympathetic nervous system (SNS) is an important component of the autonomic 
nervous system. Sympathetic outflow is driven by a network of neurons located in the 
rostral ventrolateral medulla. These neurons provide excitatory output to preganglionic 
neurons that innervate several target organs through postganglionic sympathetic fibers 
(Thorp and Schlaich, 2015).  
   The SNS plays a major role in the maintenance of the organism’s homeostasis, being 
influenced by several environmental and genetic factors (Conde et al., 2014; 
Tentolouris, Liatis and Katsilambros, 2006). SNS is responsible for controlling 
metabolic processes through regulation of the resting metabolic rate and thermogenesis, 
which leads to variations of energy states, carbohydrate consumption, and 
hyperinsulinemia levels (Thorp and Schlaich, 2015). The activation of sympathetic 
nerves innervation in the liver, pancreas, skeletal muscle and adipose tissue can also 
produce acute catabolic responses, like glycogenolysis and lipolysis (Thorp and 
Schlaich, 2015). 
   Due to the role of SNS activity in energy balance as well as several metabolic 
processes, a sympathetic overactivity might be associated to a variety of metabolic 
disorders, such as insulin resistance, T2D, hypertension, dyslipidemia, NAFLD and 
obesity (Conde et al., 2014; Esler et al., 2006; Grassi et al., 2005, 2007; Huggett et al., 
2003; Kahn and Flier, 2000; Kobayashi et al., 2010; Mancia et al., 2007; Tentolouris, 
Liatis and Katsilambros, 2006). Moreover, there is substantial evidence supporting that 
the SNS is exceedingly active in individuals with the MS and its key metabolic 
alterations, central obesity and insulin resistance (Thorp and Schlaich, 2015). 
   In fact, the SNS has been described as one of the links between the presence of 
metabolic diseases and the development and progression of insulin resistance, as several 
components of the MS are associated with an increase in sympathetic activity and 
deeply connected to a decrease in insulin sensitivity (Bin-Jaliah, Maskell and Kumar, 
2004; DeFronzo and Tripathy, 2009; Gallego-Martin et al., 2012; Mancia et al., 2007; 
Manjunath et al., 2013; Sacramento et al., 2018; Tsioufis et al., 2007). It has been 
shown that the SNS can reduce insulin sensitivity by changing hemodynamic 
parameters, like vasoconstriction, making it more difficult for insulin to reach its target. 
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Moreover, the SNS can directly and indirectly favor the appearance and progression of 
organ damage, which is part of the clinical onset of the MS (Mancia et al., 2007).  
   In metabolic diseases the increase in sympathetic activation can come from one of two 
ways, directly by the sympathetic nerve endings or indirectly by the circulating 
catecholamines (CA) (epinephrine and norepinephrine) (Conde et al., 2014; Tentolouris 
et al. 2006). CA modulate metabolism to increase blood glucose levels by stimulating 
glycogenolysis in the liver, increased glucagon secretion and decreased insulin secretion 
from the pancreas, and increased lipolysis in adipose tissue. (Conde et al., 2014; 
Tentolouris, Liatis and Katsilambros, 2006) Therefore, by a direct or indirect action, the 
SNS is associated with hyperinsulinemia, hyperleptinemia, increased FFA, 
inflammation, fatty liver and obesity, yet the mechanisms behind it remains to be 
clearly understood (Conde et al., 2014; Lambert et al., 2010). Blunted sympathetic 
responsiveness to glucose and elevated arterial noradrenaline levels are evidence for 
sympathetic overactivity, suggesting profound disturbances in central sympathetic nerve 
activity in metabolic diseases (Thorp and Schlaich, 2015). 
   Several pathophysiological mechanisms link SNS overactivity with the MS and its 
core components like central obesity and insulin resistance. The ongoing discussion as 
to whether sympathetic overactivity is a consequence or a cause of metabolic 
dysfunctions (Lambert et al., 2010; Thorp and Schlaich, 2015). As, evidence suggest 
that SNS overactivity is important both in the initiation and the maintenance of 
metabolic abnormalities seen in the MS (Thorp and Schlaich, 2015). 
 
1.4. Carotid Body 
 
   The carotid bodies (CBs) are small paired organs, located bilaterally at the  
bifurcation of the common carotid artery (Atanasova, Iliev and Lazarov, 2011; 
Gonzalez et al., 1994) (Figure 1.7.). They measure approximately 2 mm in humans and 
less than 1 mm in rats (Atanasova, Iliev and Lazarov, 2011). The CBs are capable of 
sensing and responding to changes in arterial blood gases such as hypoxia (low O2 
levels), hypercapnia (high CO2 levels), and acidosis (low blood pH) (Gonzalez et al., 
1994). To be able to sense these changes, the CBs are the most perfused organ per gram 
weight in the body (2000 mL/min per 100 mg of tissue) and receive blood via an arterial 
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Figure 1. 8. Carotid body (CB) location and innervation (A), with the celular arragenment 
(B). (adapted from Gríofa et al., 2014). 
branch arising from internal or external carotid artery (Gonzalez et al., 1994; Paton et 
al., 2013). Also, in order to respond to these changes , the CBs are innervated by the 
nerve fibers from the glossopharyngeal (carotid sinus nerve, CSN), vagal, and the 
sympathetic nerve of the nearby superior cervical ganglion (González et al., 1995; 
Kumar and Prabhakar, 2007; Paton et al., 2013).  
   The CB is organized into clusters of cells, glomeruli, which are in close proximity 
with a vast network of capillaries and connective tissue. The glomerulus are constituted 
mainly by two types of cells: the chemoreceptor cells, also known as glomus or type I 
cells, which are derived of the neural crest and are synaptically connected with the CB’ 
sensitive nerve, the CSN (Gonzalez et al., 1994) and, the type II cells or sustentacular 
cells. Type II cells formerly believed that they only had a supportive role, but recently 
has been proposed that they are adult neural stem cells that in response to a stimuli, like 
hypoxia, can proliferate and differentiate into new type I cells (Conde et al., 2014; 
Iturriaga and Alcayaga, 2004; Pardal et al., 2007; Piskuric and Nurse, 2013). 
   The stimulation of the CBs leads to the release of neurotransmitters (as CA, 
adenosine, adenosine triphosphate (ATP), serotonin, acetylcholine, neuropeptides) that 
lead to an increase in the action potential frequency of the CSN (Conde et al., 2014). 
The CSN activity is integrated in the brainstem to induce a panoply of respiratory 
reflexes in order to normalize blood gases via hyperventilation and to regulate blood 
pressure (BP) and cardiac performance via activation of the sympathetic nervous system 
(Gonzalez et al., 1994; Marshall, 1994). 
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1.4.1. Carotid Body, Metabolic Diseases and the Sympathetic Nervous 
System  
  
   It is consensual that metabolic diseases are associated with sympathetic overactivation 
(Esler et al., 2006; Lambert et al., 2010; Paton et al., 2013; Ribeiro et al., 2013; 
Tentolouris, Liatis and Katsilambros, 2006) . Also, an overactivation of the SNS is 
related with insulin resistance, but the link between these defects it is not yet fully 
understood (Egan, 2003; Iturriaga et al., 2016; Tentolouris, Liatis and Katsilambros, 
2006; Tsioufis et al., 2007, 2011). Prof. Conde group has established that the CB is the 
link between sympathetic nerve activity and insulin resistance (Ribeiro et al., 2013, 
Sacramento et al. 2017), as they showed that resection of CSN prevented and 
normalized the overactivation of the SNS induced by hypercaloric diets, measured as 
plasma and adrenal medulla catecholamines and by the measurement of heart rate 
variability (Sacramento et al., 2017).  
   In the last years, a rift of opinions has emerged regarding the effect of hypoglycemia 
(low blood glucose) on the CB. While some authors suggested that hypoglycemia is 
capable of activating the CB (Pardal and López-Barneo, 2002; Zhang, Buttigieg and 
Nurse, 2007), others suggested that hypoglycemia per se is not able to activate the CB, 
as it is incapable of altering CSN frequency of discharges in vivo and ex vivo (Bin-
Jaliah, Maskell and Kumar, 2004; Conde et al., 2014; Gallego-Martin et al., 2012). 
Additionally, it was also observed that hyperglycemia (25mM of glucose) did not 
changed either the basal CSN activity or the CSN chemosensory activity in response to 
hypoxia (0% O2), suggesting that hyperglycemia does not activate the CB nor 
potentiates the response to hypoxia (Conde, Sacramento and Guarino, 2018). 
   Recently, it was demonstrated that insulin stimulates the peripheral chemoreceptors 
located in the CB, suggesting that probably hyperinsulinemia might be a key factor 
initiating CB overactivation, leading to the increased SNS activity (Ribeiro et al., 2013). 
Insulin is capable of stimulating the CB and inducing a neurosecretory response by 
binding to the insulin receptor present in the chemoreceptor cells of the CB (Ribeiro et 
al., 2013). Insulin induces an increase in intracellular Ca2+ in the chemoreceptor cells, 
stimulating the release of ATP and dopamine from the CB (Ribeiro et al., 2013). Also, 
insulin produces a dose-dependent increase in ventilation, an effect that is abolished by 
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CSN cut (Conde et al., 2014; Guarino et al., 2013). Therefore, these results are in 
agreement with the hypothesis that insulin is a stimulus for CB activation, 
independently of glucose levels. Shifting the paradigm of CB activation from “low 
glucose” to “high insulin”.  
 
   Moreover, an overactivation of the CB can be perceived as a dysfunction of the organ, 
since, evidence suggests that CB are overactive in metabolic diseases like T2D, 
hypertension and obesity (Conde, Sacramento and Guarino, 2018; Sacramento et al., 
2017). The CB activity lead to an increase in the action potential frequency of the CSN, 
so an overactivation of these organ leads to overstimulation of the CSN (Conde et al., 
2014; Conde, Sacramento and Guarino, 2018). The CB sympatho-stimulation though 
the CSN, leads to an activation of the SNS (Sacramento et al., 2017). The CB 
overactivation has been demonstrated to be connected with the development of insulin 
resistance and glucose intolerance (Conde, Sacramento and Guarino, 2018; Ribeiro et 
al., 2013; Sacramento et al., 2018). Conde’s lab demonstrated, that by abolishing CB 
activity, with the denervation or the bioelectronic modulation of the CSN was possible 
to prevent and reverse insulin resistance (Figure 1.9.), as well as glucose intolerance 
(Table 1.3) in young animals with prediabetes and in an early stage of T2D (Ribeiro et 
al., 2013; Sacramento et al., 2017, 2018).  
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Figure 1. 9. Effect of the carotid sinus nerve (CSN) resection on the insulin sensitivity. Effect 
of CSN resection on insulin sensitivity assessed by an insulin tolerance test (ITT) and expressed 
as the constant rate for glucose disappearance (KITT) in young controls (CTL) (A) and HFHSu (B) 
animals. CSN resection was performed at 14 weeks of diet and animals were maintained under 
their respective diets until the 25 weeks. Black line, control sham; Black dotted line, control with 
CSN resection; Grey line, HFHSu sham; Grey dotted line, HFHSu with CSN resection. Data are 
means ± SEM of 8-10 animals. One and Two-Way ANOVA with Dunnet’s and Bonferroni 
multicomparison test, ***p<0.001 vs without CSN resection (Sacramento et al., 2018). 
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Table 1.3. Area under the curve (AUC) obtained from the analysis of the glucose excursion 
curves in young control (CTL) and high-fat high-sucrose (HFHSu) animals with or 
without carotid sinus nerve (CSN) resection (Sacramento et al., 2018). 
  
 
 
 
 
 
 
 
 
 
 
   Conde’s lab not only showed that the modulation of the CSN prevents and reverses 
insulin resistance and glucose intolerance, but also that improves plasma fasting glucose 
(Table 1.4.) and decreases perinephric fat accumulation (Table 1.5.) (Sacramento et al., 
2018). 
 
 Table 1.4. Effect of carotid sinus nerve resection (CSN) on plasma fasting glucose (mg/dl) 
in control (CTL) and HFHSu young animals (Sacramento et al., 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are means ± SEM of 8-10 animals. One and Two-Way ANOVA with Dunnet’s and 
Bonferroni multicomparison test: **p<0.01, vs control; †p<0.05, with vs without CSN 
resection.   
Data are means ± SEM of 8-10 animals. One and Two-Way ANOVA with Dunnet’s and 
Bonferroni multicomparison test, ***p<0.001 vs control; †p<0.05 vs without CSN resection; 
ǂp<0.05 vs without CSN resection at 25 weeks of diet.  
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Table 1.5. Effect of carotid sinus nerve (CSN) resection on total, perinephric, perienteric 
and epididymal fat in control and HFHSu young animals (Sacramento et al., 2018). 
 
 
 
 
   These results demonstrated that the overactivation of the CB is in the genesis of 
insulin resistance and of the decreased of peripheral insulin action seen in metabolic 
disorders, like T2D, prediabetes and MS (Ribeiro et al., 2013; Sacramento et al., 2017). 
Also, these results highlight that the link between the CB and the SNS must be further 
investigated to better understand its role on the control of glucose metabolism, insulin 
resistance and metabolic disturbances. They also highlight that the modulation of the 
CB activity might arise as a new therapeutic approach for the treatment of 
sympathetically mediated diseases.  
 
1.5. Aging  
 
   Aging is described as a series of morphological and functional changes over time 
(Bonomini, Rodella and Rezzani, 2015; Guarner and Rubio-Ruiz, 2011). It is seen as a 
biological process characterized by a progressive deterioration in physiological 
functions, with a decline in maintenance of homeostasis, accompanied by an array of 
metabolic changes, including insulin resistance, changes in body composition and 
modulation of mitochondrial function (Barzilai et al., 2012; Bonomini, Rodella and 
Rezzani, 2015; Finkel, 2015). These changes contribute to an increased predisposition 
to age-related conditions, like T2D, hypertension, and CVD (Bonomini, Rodella and 
Rezzani, 2015; Finkel, 2015; Riera and Dillin, 2015). Also, several disorders whose 
prevalence increase with aging, such as obesity, insulin resistance, inflammation, 
Data are means ± SEM of 8/10 animals. One and Two-Way ANOVA with Dunnet’s and 
Bonferroni multicomparison test, **p<0.01, ***p<0.001 vs control; †p<0.05 vs without CSN 
resection. 
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changes in the activity of the hypothalamus-hypophysis suprarenal axis, stress and 
hypertension, also contribute to an increase of the metabolic diseases prevalence 
(Bonomini, Rodella and Rezzani, 2015; Guarner-Lans et al., 2011; Guarner and Rubio-
Ruiz, 2011). 
   Insulin resistance, a major component of MS and T2D, is commonly observed in older 
people (Barzilai et al., 2012; Morley, 2008). It is described in humans and animal 
studies that aging is associated with a progressive decline in insulin action and a 
decrease in insulin sensitivity (Barzilai et al., 2012; Escrivá et al., 2007; Guarino et al., 
2013; Morley, 2008; Santulli et al., 2012). A possible hypothesis for the association 
between aging and insulin resistance comprehends four main pathways: environmental 
causes, mainly diet styles and physical activity; anthropometric changes, it is well 
known that aging is associated with a relative increase in body fat and a decrease in lean 
body mass, muscle tissue especially, which leads to a reduction in active metabolic 
tissue; neuro-hormonal variations, with age comes a decline in plasma insulin-like 
growth factor-1 (IGF-1) and dehydroepandrosterone sulphate (DHEAS), which might 
have an effect opposite to that of insulin at the skeletal muscle and adipose tissue levels; 
and finally the rise in oxidative stress with age (Barbieri et al., 2001). Additionally, a 
decrease in glucose tolerance with age has been recognized since 1920 (DeFronzo, 
1981). Results obtained in older subjects submitted to an oral glucose tolerance test 
demonstrated that the ability to metabolize glucose is impaired in these subjects 
(DeFronzo, 1981). Therefore, aging is associated to a progressive decline in glucose 
tolerance, triggered by a tissue desensitization to insulin (Barzilai et al., 2012; 
DeFronzo, 1981).  
   The aging process is altered or accelerated in metabolic and cardiovascular diseases. 
MS is accompanied with vast systemic complications but it is also associated with an 
early aging (Bonomini, Rodella and Rezzani, 2015; Guarner-Lans et al., 2011; Guarner 
and Rubio-Ruiz, 2011; Nunn, Bell and Guy, 2009). Although, aging and the 
development of insulin resistance are seem to be accelerated in the MS, the mechanisms 
behind the precocious aging in MS remain elusive (Fadini et al., 2011; Guarner-Lans et 
al., 2011; Guarner and Rubio-Ruiz, 2011). 
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   Abdominal obesity, commonly observed with aging, is a major contributor to insulin 
resistance and MS (Barzilai et al., 2012; Folsom et al., 1993). Moreover, aging is 
associated with an increase in bodyweight, especially in subcutaneous and visceral body 
fat and studies have shown that when obesity is present there is an upregulation of the 
aging pathways (Catalano, Bergman and Ader, 2005; Guarner and Rubio-Ruiz, 2011). 
Additionally, individuals with obesity have a greater risk for the development of T2D, 
CVD, hypertension and hypercholesterolemia, and vice versa (Ryan, 2000). 
   Aging is also associated with an increase in proinflammatory cytokines, which are 
known to interfere with insulin action (Barzilai et al., 2012). This increase results from 
the age-associated accumulation of visceral fat but also from the increasing numbers of 
senescent cells (Barzilai et al., 2012; Sepe et al., 2011). Hence, inflammation is a key 
factor in the progressive loss of lean tissue and impaired immune function observed in 
aging. An elderly immune system becomes highly susceptible to chronic inflammatory 
reactions and is less able to respond to an acute event of new antigens (Guarner and 
Rubio-Ruiz, 2011; Martinis et al., 2005; Wu et al., 2007). There are several 
predisposing factors for the chronic inflammation that occurs during aging, including, 
increased oxidative stress and an increased incidence of asymptomatic bacteriuria 
(Martinis et al., 2005). In addition, to produce more inflammatory cytokines, adipocytes 
from old mice induce a higher inflammatory response in other cells (Wu et al., 2007). 
   These age-related alterations in metabolism and body fat distribution are active 
participants in a vicious cycle that can accelerate the aging process and the onset of MS, 
insulin resistance and cardiovascular diseases, making MS of predominant importance 
as a growing epidemic in a worldwide aged population (Barzilai et al., 2012; Bonomini, 
Rodella and Rezzani, 2015; Haffner and Taegtmeyer, 2003). 
 
1.5.1. Aging and Carotid Body 
 
   The CB might play an important role during aging, as this organ has the ability to 
influence body homeostasis (Barzilai et al., 2012; Bonomini, Rodella and Rezzani, 
2015; Finkel, 2015; Giulio et al., 1974). Ageing also increases  the predisposition to 
age-related conditions, like T2D, hypertension, and CVD (Bonomini, Rodella and 
Rezzani, 2015; Finkel, 2015; Riera and Dillin, 2015).  Knowing that the deregulation of 
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the CB is linked to an overactivation of the SNS and to metabolic diseases (Conde, 
Sacramento and Guarino, 2018; Sacramento et al., 2017), the CB might have a critical 
role in age-induced metabolic dysfunctions. 
   The aging CB shows an attenuated response to hypoxia and suffers age-dependent 
structure modifications (Giulio et al., 1974; Giulio, Di et al., 2003). Ultimately, aging 
leads to CB adaptation through a reduction to the sensitivity to stimuli (Giulio et al., 
1974; Giulio, Di et al., 2003). So the overall basal oxygen reduction of body 
requirements may be a mechanism of cellular self-protection to the accumulation of 
reactive oxygen species (ROS) during aging (Giulio et al., 1974; Giulio, Di et al., 
2003). Moreover, aging leads to a reduction in synaptic connections between 
chemoreceptor cells, as well as a reduction of nerve conductivity (Finkel and Holbrook, 
2000; Giulio et al., 1974, 2012; Giulio, Di et al., 2003; Rivner, Swift and Malik, 2001). 
Also, the maximum number of impulses per minute in nerves generally decrease and so 
does sensitivity by peripheral receptors, leading to a reduction of the homeostatic 
capacity with higher latency to stimuli (Finkel and Holbrook, 2000; Giulio et al., 1974, 
2012; Giulio, Di et al., 2003; Rivner, Swift and Malik, 2001). 
   The aged CB also shows a decrease in the number of cells associated with an increase 
in extracellular matrix, a reduction in number and volume of type I cells as well as in 
mitochondria (Dymecka, Walsky and Pokorski, 2006; Giulio et al., 1974; Giulio, Di et 
al., 2003; Sacramento et al., 2019). Pokorski et al. showed advanced degenerative 
morphological changes in the CB’s parenchyma, affecting predominantly the type I cell, 
the ones with the chemoreceptor capacity, whereas type II CB cells remain unaltered 
(Giulio et al., 1974; Pokorski et al., 2004). These factors suggest that the CB becomes 
less responsive, which could explain the observed decrease in chemosensory responses 
during aging (Giulio et al., 1974). Also, Conde et al. demonstrated that in spite of an 
enlargement of the organ, there is an age-dependent decrease in parenchymatous tissue 
evident after 12 months of age (Conde et al., 2006). The enlarged CB showed a higher 
CA content and turnover time and reduced responsiveness to hypoxic stimuli (Conde et 
al., 2006; Sacramento et al., 2019).  
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   Recently, it has been shown in young animals with prediabetes and in an early stage 
of T2D that the abolition of the CB activity through the CSN resection or the 
bioelectronic modulation of CSN activity prevented and restored the insulin sensitivity 
and glucose tolerance (Ribeiro et al., 2013; Sacramento et al., 2017, 2018). With the 
social burden of metabolic diseases and the increasing prospective with age it is 
imperative to explore the abolishment of CB activity in older rats as a potential 
therapeutic intervention in metabolic diseases. Therefore, further studies are required to 
fully clarify the role and value of the CB activity in age-induced metabolic 
dysfunctions, as this organ suffers its own modifications with age.  
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2. Aims 
 
   The metabolic diseases are a major public-health epidemic with increasing incidence 
and prevalence worldwide. Aging itself leads to a greater predisposition for these 
conditions, like T2D, NAFLD hypertension, CVD, obesity and insulin resistance. 
Therefore, it is of significant importance to find new therapeutic targets for these 
diseases in an aged world population. Knowing that an overactivation of CB activity 
and consequent increase in the SNS activity is associated with the development of 
insulin resistance and glucose intolerance in young rats, and that the CSN resection 
prevents and reverts these metabolic features, the general aim of this thesis was to 
investigate the impact of the abolishment of CB activity in metabolic function in older 
rats as the modulation of CSN activity might be a potential therapeutic intervention in 
metabolic diseases, like T2D, dyslipidemia and NAFLD in aging.  
 
   The specific aims of this thesis are: 
• To evaluate the impact of long-term hypercaloric diets consumption on glucose 
homeostasis in old animals. 
• To study the effect of the CSN resection on age-induced metabolic dysfunction 
in 15 months old rats. 
• To investigate the effect of long-term hypercaloric consumption on liver 
function in young and old animals. 
• To evaluate the effect of the CSN resection on liver function in control and long-
term hypercaloric consumption young and old rats. 
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Figure 3. 1. Representative scheme of the experimental protocol performed on Wistar rats 
of 25 and 53 weeks and their respective diets.  
3. Methods 
3.1. Animal Model and Experimental Procedure 
 
   Experiments were performed in male Wistar rats, ageing 8-10 weeks old, acquired 
from the NOVA Medical School|Faculdade de Ciências Médicas, Universidade Nova de 
Lisboa animal house. The animals were divided randomly into two groups (Figure 3.1.): 
two control (CTL) groups that were fed with a standard diet (7.4% fat + 75% 
carbohydrate (4% sugar) + 17% protein, Probiológica, Sintra, Portugal) and two high-
fat high-sucrose (HFHSu) groups that were fed with a lipid-rich diet (60% energy from 
fat): 34.9% fat + 25.9% carbohydrate + 23.1% protein; TestDiet, St. Louis, USA) plus 
sucrose (35%) in drinking water, during 14 and 44 weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   After the respective diet periods the animals were randomly divided and half of the 
group was submitted to a surgical procedure to chronically resect the CSN and the other 
half to a sham surgical procedure, in which the animals were submitted to the same 
protocol but in which the nerves remained intact.   
Male Wistar rats (8 - 10 weeks)
HFHSu Diet
Standard Diet
44 Weeks
Surgical Procedure
Control sham
Control CSN resection
HFHSu sham
HFHSu CSN resection
Chronic bilateral CSN 
resection
HFHSu Diet
Standard Diet
14 Weeks
Control sham
Control CSN resection
HFHSu sham
HFHSu CSN resection
25 Weeks
52 Weeks3
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   The surgical protocol includes: intraperitoneal anesthesia with medetomidine (0.5 
mg/kg) (Sedator©, Siloal, Coimbra, Portugal) and ketamine (75 mg/kg) (Nimatek©, 
Dechra, Northwich, United Kingdom) and its reversion with antipamezole (0.25mg/kg, 
i.p.) (Antisedan©, Esteve, Lisbon, Portugal). After surgery, when the animals were 
awake an analgesic, buprenorphine (10 mg/kg, s.c.) (Bupaq©, Richter pharma, 
Budapest, Hungary), was administered. Additionally, rats were treated post-operatively 
for 2-3 days with an anti-inflammatory drug carprofen (5 mg/kg, s.c.) (Rimadyl©, 
Zoetis, New Jersey, USA).  
   Animals were maintained on their respective diets after the surgery during nine weeks 
in old animals and 11 weeks in young animals. The difference in post-surgical periods 
is due to the regeneration of the CSN. The study in young animals was performed 
previously (results already published in Sacramento et al. 2018) and the rats were 
maintained for 11 weeks after the surgery. However, the CSN starts to regrow 6 days 
after being cut and usually it completely regenerates after 11–12 weeks (Zapata, 
Stensaas and Eyzaguirre, 1976). Therefore, in the following studies the post-surgical 
period was altered to 9 weeks, the time used in the present study in aged animals.  At 
the end of this period, which corresponds to 25 and 53 weeks on diet, the animals were 
submitted to a terminal experiment, in which animals were anesthetized with 
pentobarbital sodium (60 mg/kg i.p.) (Eutasil©, Ceva, Libourne, France) and blood was 
collected by heart puncture and  tissues such as the liver, soleus and gastrocnemius, 
diaphragm and visceral, perinephric, epidydimal and brown adipose tissues (BAT) 
(collected from the interscapular region), brain and hypothalamus samples were rapidly 
collected and stored at -80 ºC until posterior analysis. A smaller portion of the liver, 
BAT and white adipose tissue (WAT) were immediately set aside and preserved in 
formalin (4ºC). Plasma was collected to ethylenediaminetetraacetic acid (EDTA) 
precoated tubes, and kept on ice. After, the plasma samples were centrifuged (Sigma, 
Madrid, Spain) at 3,000 × g for 10 min (4 °C) and stored at −80 °C in an ultralow 
freezer (Guarino et al., 2013). 
   Caloric and liquid intake, body weight and animal behavioral changes were assessed 
once a week, before and after the surgical procedure in all groups of animals. 
Additionally, insulin sensitivity and glucose tolerance were evaluated throughout the 
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experimental protocols by an insulin tolerance test (ITT) and an oral glucose tolerance 
test (OGTT), respectively.  
 
   Principles of laboratory care were followed in accordance with the European Union 
Directive for Protection of Vertebrates Used for Experimental and Other Scientific Ends 
(2010/63/EU). Experimental protocols were approved by the Ethics Committee of the 
NOVA Medical School. 
 
3.2. Metabolic Evaluation 
3.2.1. Measurement of the Insulin Sensibility  
 
   The ITT provides an estimation of the insulin sensitivity in vivo. For the ITT, the 
animals were fasted overnight with free access to water. In the morning, the basal 
glycemic levels were measured and afterwards a bolus of insulin (0.1 U/kg, Humulin® 
R 100IU/ml, Lilly) was administrated in the tail vein of the animals (Monzillo et al., 
2003; Sacramento et al., 2015). Glycemia levels were then measured every minute 
during 15 minutes and the decrease of the plasmatic glucose concentration examined. 
The blood was collected by tail tipping and evaluated using a glucose meter (Precision 
Xtra Meter, Abbot Diabetes Care, Portugal) and test strips (Abbot Diabetes Care, 
Portugal). The constant rate for glucose disappearance (KITT) was used to evaluate the 
insulin sensitivity, knowing that when the KITT is > 3.5 means that the animals are 
insulin sensitive and when the KITT is < 3.5 the animals are insensitive to insulin action, 
meaning that the animals are insulin resistant. The constant is obtained from the 
equation:  
 
 
   In which the value of the glucose half-time ( ) represents the mean lifetime of the 
glucose and was calculated from the slope of the curve during the linear phase of the 
plasma glucose disappearance by the analysis of the least squares method (Monzillo et 
al., 2003; Sacramento et al., 2015).  
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3.2.2. Measurement of Glucose Tolerance 
 
   Animal glucose tolerance was evaluated through an OGTT. The OGTT allowed to 
determine the glucose tolerance and subsequently the speed of release of insulin and its 
action in the peripheral tissues (Monzillo et al., 2003).  
   The OGTT consisted in the administration of a glucose solution (2 g/kg) by gavage to 
overnight fasted animals. The blood glucose levels were measured by tail tipping before 
the glucose administration and at 15, 30, 60, 120 and 180 minutes after the gavage 
(Kinzig, Honors and Hargrave, 2010). The glucose tolerance was evaluated as the area 
under the curve (AUC) of the glucose excursion curves.  
 
3.3. Lipid profile Evaluation 
 
   Lipid profile was determined using the plasma collected from the animals previously 
centrifuged and a RANDOX kit (RANDOX, Porto, Portugal), where the total 
cholesterol and TG were measured by a trinder-based colorimetric end-point assays 
(Sacramento et al., 2017). 
 
3.4. Liver´s Lipid Quantification 
3.4.1. Liver´s Total Lipid Content  
 
   In order to evaluate and compare the total liver lipid content a modified protocol 
described by Folch was used (Folch, Lees and Sloane Stanley, 1957). Briefly, a portion 
of the liver was homogenized (Tube A) using an automatic homogenizer (IKA, 
Germany) in Folch’ solution (Chloroform: Methanol 2: 1 v/v). 
   The homogenization of the tissue was always performed with the following 
proportions: 3 ml of Folch’ solution per 0.5 g of liver.  
   Afterwards, the samples were shaken for 2 hours in an automatic shaker and filtered 
with filter paper into another glass test tube (Tube B). Then, to the tissue remaining in 
the tube A 2.5 ml of the Folch’ solution was added, and the mixture was stirred again 
for 2 hours, and then filtered. This procedure was repeated twice (Figure 3.2.), always 
collecting the filtrate into the tube B.  
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   Subsequently, to the filtrates collected in the 
tube B was added 2 ml of 0.73% NaCl, after 
which the tube was stirred vigorously and left to 
rest overnight. After the resting period, was 
possible to observe two phases in the tube B, the 
organic and aqueous phase. On the top was 
located the aqueous phase, predominantly 
composed of water and methanol, whereas the 
lower or organic phase, mainly composed of 
chloroform, possesses the capacity to retain the 
lipids. (Liquid Extraction: Folch). Therefore, the 
phase located at the bottom of the tube B was 
collected to a previously weight tared 
eppendorf.  
   Furthermore, to the phase remaining in the 
tube B it was added a solution of Folch’s 
reagent: NaCl 0.53% (80:20), which was stirred 
and left to rest for 2 hours. Afterwards, the 
organic phase was collected to the same 
eppendorf in order for it to dry. Finally, the 
eppendorfs were weighted again and the 
percentage of lipids in the tissue was 
determined, according to the initial liver´s 
weight used in the experiment. 
 
3.4.2. Liver´s Triglyceride Content  
 
   The triglyceride content of the livers was evaluated using the final dried samples of 
the analysis of the liver’s total lipid content with the Triglyceride Assay Kit-Bulk 500 
Point Assay Kit (ZENBIO, NC, USA). 
 
 
Figure 3. 2. Scheme from the Folch’ 
adapted protocol. The liver homogenates 
contained in tube A were shaken for 2 
hours and filtered into glass test tube B. To 
the tissue remaining in the tube A 2.5 ml of 
the Folch’ solution was added, and the 
mixture was stirred again for 2 hours, and 
then filtered. This procedure was repeated 
twice, always collecting the filtrate into the 
tube B. 
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3.5. Histologic Analysis  
 
After collecting and preserving the tissues in formalin for at least 72 hours at 4ºC the 
tissues were sent to the histology facility at CEDOC. The livers were divided into two 
sections: half for paraffin embedding tissue sections and the other half to be crio 
preserved. The crio preserved samples were embedded in optimal cutting temperature 
(OCT) compound and snap frozen in liquid nitrogen and kept at -80ºC for posterior 
analysis. 
   For the preparation of tissue sections for hematoxylin & eosin (H&E) staining, the 
tissues were embedded in blocks of paraffin. For the treatment of the samples and the 
paraffin processing the Automated Leica Tissue Processor© (TP1020) was used. The 
samples are placed in cassettes and then emerged in the cylindric canisters of the 
Automated Leica Tissue Processor©. The samples stayed 1:30 hours in each cannister 
and the same solution was put into two subsequent cannisters. The first canister is filled 
with alcohol 70% to dehydrate the samples, next they are emerged into a new solution 
of alcohol 70%. After the samples were submerged into alcohol 96% and then again 
into the a new cannister with the same solution. Next, following the same procedure the 
samples were put into alcohol 100%, xylene (klinipath, Gelderland, Nederland) and to 
finish into paraffin at 70ºC (Diapath, Bergamo, Italy). The liver samples were cut in 3 
µm thickness in the microtome (Microm HM 200) and placed in the slides.  
   For the H&E staining the slides containing the sample were deparaffinized in xylene 
for 15 minutes and hydrated by been immersed for 30 seconds in each alcohol (100%, 
96% and 70%) and finally, in distilled water for 5 minutes. The slides were emerged in 
Harris Hematoxylin (Merck, New Jersey, USA) for 10 minutes, then dipped in distilled 
water to remove the excessive stain. After, they were differentiated in Acid Alcohol 1% 
with 3 dips (1 second each) and were washed in running tap water for 5 minutes. Then, 
the slides were dipped in Alcohol 70% and four times (1 second each) in Alcoholic 
Eosin Y (Sigma-Aldrich, Missouri, USA). The slides were dehydrate in alcohol (70%, 
96%, 100%) 30 seconds each and cleared in xylene. Finally, the slides were left to set 
for at least 10 minutes before they were sealed with the lamella. The H&E staining 
marked the nuclei with blue and the cytoplasm with pink. The slides and paraffin blocks 
were kept at room temperature. 
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   After liver H&E slides preparation they were sent to Instituto de Medicina Molecular 
(IMM) where they were analyzed for the presence of hepatocellular damage, fibrosis, 
fatty change and inflammation according with table 3.1. 
 
Table 3.1. Hematoxylin and Eosin (H&E) Liver Scores 
 
Hepatocellular 
damage scores 
Fibrosis 
scores 
Fatty change/ 
Steatosis scores 
Immune cell 
infiltration scores 
1: minimal 1: minimal 1: minimal 1: minimal 
2: mild 2: mild 2: mild 2: mild 
3: moderate 3: moderate 3: moderate 3: moderate 
4: marked 4: marked 4: marked 4: marked 
5: extreme 5: extreme 5: extreme 5: extreme 
 
3.6. Data Analysis 
 
   The data analysis was assessed with Graph Pad Prism Software version 6 (GraphPad 
Software Inc., San Diego, CA, USA) and shown as the mean values with their standard 
errors (Mean ± SEM). The significance of the differences between the mean values was 
calculated by one- and two-way ANOVA with Bonferroni multiple comparison tests. 
Differences were considered statistically significant at p<0.05.  
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4. Results  
 
   In the present thesis the impact of long-term diet consumption and CSN resection on 
body weight gain, fasting glucose, insulin sensitivity, glucose tolerance and fat depots 
were  studied in rats fed with a standard or HFHSu diet during 53 weeks was evaluated. 
However, since this study also focus on the effect of age and long-term hypercaloric 
consumption in the liver metabolism, samples of liver collected from HFHSu animals 
submitted to hypercaloric diets during 25 weeks and CSN resection from a previous 
study were used to analyzed the total liver lipid content, liver TG and cholesterol as 
well as lipid deposition, inflammation and fibrosis.   
 
4.1. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on body weight 
 
   Figure 4.1. describes the effect long-term hypercaloric intake and the effect of the 
chronic CSN resection on body weight in aged animals (Figure 4.1 A and B).The 
standard diet with 2.56 Kcal/g was able to stimulate an increase in CTL rats before the 
surgery (CTL before sham surgery =1.33±0.07g/day; CTL before CSN denervated 
=1.21±0.03g/day) (Figure 4.1 B). Body weight decreased by 63.40% with sham surgery 
in control animals and by 102.63% with CSN resection . Hypercaloric diet, with 6.46 
Kcal/g, increased as expected body weight of the animals (HFHSu sham 
=1.44±0.22g/day; HFHSu CSN denervated =1.52±0.37g/day) (Figure 4.1 B), an effect 
that was reduced by 47.22% after the sham surgery and 90.21% after the CSN resection 
. 
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Figure 4. 1. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on the body weight (A) and body weight change in old controls (C TL) 
and HFHSu animals. (A) Black line with dots represent body weight of CTL animals without 
CSN resection; dotted black line with squares represent body weight of CTL animals with C SN 
resection; grey line with triangles represent body weight of HFHSu animals without CSN 
resection; dotted grey line with inverted triangles represent body weight of HFHSu animals with 
CSN resection. (B) White bars represent the change in body weight before the CSN resection 
and sham procedure; black bars represent the change in body weight after the CSN resection 
and sham procedure. Bars represent mean±SEM of 1-6 values. One- and Two-Way ANOVA 
with Bonferroni multicomparison tests; #p<0.05, ##p<0.01 and ####p<0.0001 comparing 
within the group . 
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4.2. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on fasting glucose in old animals 
 
   Table 4.1. shows the effect of long-term hypercaloric diet intake and the chronic CSN 
resection on plasma fasting glucose in old animals. Previously, Sacramento et al. 
(2017), observed, in young animals, a 13.96% increase in plasma fasting glucose with 
hypercaloric diet consumption and a reduction of 10.42% with the CSN resection 
(Sacramento et al., 2017). Herein, in old animals neither long-term hypercaloric diet 
consumption nor  CSN resection had impact in fasting glycemia. 
 
Table 4.1. Effect of carotid sinus nerve resection (CSN) on fasting glucose (mg/dl) control 
(CTL) and HFHSu animals. 
 
 CTL HFHSu 
 
Without CSN 
resection 
With CSN 
resection 
Without CSN 
resection 
With CSN 
resection 
Before diet 77.00 ± 2.39 76.50 ± 4.50 79.20 ± 2.04 76.00 ± 2.80 
44 weeks of 
diet 
87.88 ±3.32 87.33 ± 8.41 86.22 ± 5.03 87.63 ± 3.09 
9 weeks after 
surgery 
84.57 ± 6.35 83.75 ± 2.29 87.50 ± 3.96 84.43 ± 4.358 
 
 
4.3. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on insulin sensitivity in old animals 
 
   Figure 4.2. shows the effect of long-term hypercaloric diet intake as well as the effect 
of the chronic CSN resection on insulin sensitivity in old animals.  
   As expected, age induced a 59.11% decrease in insulin sensitivity from a control 
value of 4.50±0.36% glucose/min (Figure 4.2. A). When the effects of age and diet were 
combined, insulin resistance was not significantly aggravated (KITT CTL 44 weeks of 
Data are means±SEM of 4-8 values.  
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diet=1.84±0.11% glucose/min; KITT HFHSu 44 weeks of diet=1.73±0.18% glucose/min) 
(Figure 4.2. A and B).  
   Figure 4.2.C and D shows that effect of the chronic bilateral CSN resection on ageing 
animals.  After the 9 week period of follow-up the control and HFHSu animals 
submitted to the sham procedure remained insulin resistant (Figure 4.2. A and B), with 
KITT values similar to values before the surgery (KITT CTL Sham 44 weeks of 
diet=1.84±0.11% glucose/min; KITT CTL 44 weeks of diet without CSN resection=2.20 
± 0.16%glucose/min; KITT HFHSu Sham 44 weeks of diet=1.73±0.18 % glucose/min; 
KITT HFHSu 44 weeks of diet without CSN resection=2.05 ± 0.24%glucose/min). 
   It can be clearly seen that CSN denervation restores insulin sensitivity in old animals 
and in old animals submitted to long-term hypercaloric diet consumption.   
Furthermore, the restoration was maintained along the 9 weeks follow-up, starting in the 
first weeks after the surgery (Figure 4.2. C and D). In both groups, at the end of the 9 
week follow-up period the restore of the insulin sensitivity was maintained (KITT CTL 
before diet= 4.30±0.26% glucose/min; KITT CTL 44 weeks of diet with 9 week CSN 
resection=4.02±0.37% glucose/min; KITT HFHSu before diet=4.38±0.19% glucose/min; 
KITT HFHSu 44 weeks of diet with 9 week CSN resection=4.30±0.18% glucose/min) 
(Figure 4.2. C and D).   
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Figure 4. 2. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on the insulin sensitivity in old controls (CTL) and HFHSu animals.  
Control (A) and high-fat high-sucrose (HFHSu) (B) old animals submitted to a sham 
procedure. C and D) control and HFHSu old animals submitted to the CSN resection, 
respectively.  White bars represent the insulin sensitivity values before the diet, black bars 
represent the insulin sensitivity values of animals with 44 weeks of their respective diets and 
grey bars represent the insulin sensitivity values of the weeks after the CSN resection. Bars 
represent mean±SEM of 4-8 values. One- and Two-Way ANOVA with Bonferroni 
multicomparison tests; ***p<0.001 and ****p<0.0001 vs control (before diet); ##p<0.01, 
###p<0.001 and ####p<0.0001 vs  44 weeks of diet. 
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4.4. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on glucose tolerance in old animals 
 
   Figure 4.3. and Table 4.2. exhibit the effect of long-term hypercaloric diet intake and 
the effect of the chronic CSN resection on glucose tolerance.  
   Age did not modify glucose tolerance (AUC CTL before diet= 21800.75 ±804.43 
mg/dl*min; AUC CTL 44 weeks diet=22358.46 ±685.70 mg/dl*min) (Figure 4.3. A, 
Table 4.2) in rats, however the combination of ageing and diet induced a decrease of 
21.19 % in glucose tolerance (Figure 4.3. B. Table 4.2).  
   CSN resection was shown to improve glucose tolerance, as AUC values obtained 
from glucose excursion curves showed a decrease of 18.85% and 21.38% with the CSN 
resection both in CTL and HFHSu old animals, respectively (Figure 4.3. C and D; Table 
4.2).  CSN resection was able to revert glucose intolerance in the old HFHSu. 
Moreover, in the animals submitted to the sham procedure it was not observed any 
significant change in glucose tolerance with the surgery (Figure 4.3. A and B, and Table 
4.2.). 
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Old HFHSu with CSN resection Old CTL with CSN resection 
C 
B A 
D 
Old CTL without CSN resection Old HFHSu without CSN resection 
Figure 4. 3. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on glucose tolerance in controls (CTL) and high-fat high-sucrose 
(HFHSu) aged-animals. Control (A) and HFHSu (B) old animals submitted to a sham 
procedure. C and D) control and HFHSu old animals submitted to the CSN resection, 
respectively. Black line represents the glucose tolerance values of animals before the diets, 
black dotted line represent the glucose tolerance values of animals with 44 weeks of diet and 
the grey line represent the glucose tolerance values of animals after the sham procedure (A and 
B) and after the CSN resection (C and D). Bars represent mean±SEM of 4-8 values. One- and 
Two-Way ANOVA with Bonferroni multicomparison tests.  
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Table 4.2. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on the Area under the curve (AUC) obtained from the analysis of the 
glucose excursion in controls (CTL) and high-fat high-sucrose (HFHSu) aged-animals. 
 
 CTL HFHSu 
 
Without CSN 
resection 
With CSN 
resection 
Without CSN 
resection 
With CSN 
resection 
Before Diet 21800 ± 804 21945 ± 618 21624 ± 543 21778 ± 695 
44 weeks of diet 22671 ± 974 21655 ± 429 26953 ± 1705* 28111 ± 2035* 
9 weeks post-
surgery 
20039 ± 1012 17574 ± 1003** 25845 ± 1128 22101 ± 1123# 
 
 
 
4.5. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on fat deposition in old animals 
 
In Table 4.3. are depicted the values of the weight of the different fat depots collected 
from animals after a terminal experimental procedure. Long-term hypercaloric diet 
consumption increased the amount of total fat by 69.70%, 115.07% the perinephric fat, 
50.15% the perienteric fat and by 39.38% the epididymal fat.  CSN resection did not 
modify the fat content in both control and HFHSu old animals. 
 
 
 
 
 
 
 
 
Data are means±SEM of 4-8 values. Two-Way ANOVA with Bonferroni multicomparison tests; 
*p<0.05 and **p<0.01 vs before diet and #p<0.05 vs 44 weeks of diet. 
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Table 4.3. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on total, perinephric, perienteric and epididymal fat in control and 
HFHSu old animals. 
 
 
 
4.6. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on total cholesterol and triglycerides in young and 
old animals 
 
   Figure 4.4. describes the effect of age, long-term hypercaloric intake and the effect of 
the chronic CSN resection on lipid profile. Ageing seems to increase total cholesterol 
levels although non-statistical differences were obtained (p =0,1520). However, when 
ageing was combined with the long-term consumption of a hypercaloric diet it increases 
the levels of total cholesterol by 35.39%. CSN denervation had no impact on total 
cholesterol levels in young or old animals, but in old animals submitted to hypercaloric 
diets CSN denervation decreases cholesterol levels by 26.40% (Figure 4.4. A). Ageing 
induced a non-significant statistical increase of 78.92% in TG (CTL 25 weeks = 79.73 ± 
12.58 mg/dl; CTL 53 weeks = 142.65±32.35 mg/dl). Hypercaloric diet consumption 
increased by 69.82% plasma TG in young animals (HFHSu 25 weeks=134.40 ±32.35 
mg/dl) and by 49.09% in old animals (HFHSu 53 weeks=118.87±19.33 mg/dl). CSN 
 CTL HFHSu 
 
Without CSN 
resection 
With CSN 
resection 
Without CSN 
resection 
With CSN 
resection 
Total fat (g/kg) 83.08 ± 14.20 75.27 ± 8.18 140.99 ± 7.43** 138.69 ± 7.31 
Perinephric fat 
(g/kg) 
32.84 ± 5.91 28.79 ± 4.12 70.63 ± 6.71*** 67.64 ± 5.91 
Perienteric fat 
(g/kg) 
19.82 ± 3.58 19.14 ± 1.24 29.76 ± 1.98* 29.82 ± 2.45 
Epididymal fat 
(g/kg) 
29.13 ± 4.01 27.34 ± 3.95 40.60 ± 2.82* 41.23 ± 0.95 
Data are means±SEM of 6-8 values. Two-Way ANOVA with Bonferroni multicomparison tests; 
*p<0.05, **p<0.01 and *** p<0.001 vs control without CSN resection. 
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resection restored or even lowered below control levels, plasma TG in all groups of 
animals (TG HFHSu 25 weeks with CSN resection =79.18±29.35 mg/dl, TG CTL 53 
weeks with CSN resection =53.80±0 mg/dl; TG HFHSu 53 weeks with CSN 
resection=40.26 ±9.56 mg/dl), without affecting control young animals (Figure 4.4. B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.8. Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on total lipid and triglycerides content in the liver 
in young old animals 
 
   Figure 4.5. shows the effect of long-term hypercaloric diet intake and the effect of the 
chronic CSN resection on the liver´s lipid content in young and old animals. Ageing 
increased significantly by 101.35% lipid deposition in the liver. Also, hypercaloric diet 
consumption increase the percentage of total lipids in the liver by 47.97% and 83.56%, 
A  B         
25 weeks                53 weeks 25 weeks                53 weeks 
Figure 4. 4. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on the plasmatic lipid profile of young and old animals: total cholesterol (A) 
and triglycerides (B) plasma levels. White bars represent the values of animals without CSN 
resection, black bars represent the values of animals with CSN resection. Bars represent 
mean±SEM of 1-10 values. One- and Two-Way ANOVA with Bonferroni multicomparison tests; 
*p<0.05 and**p<0.01 vs CTL 25 weeks; #p<0.05 and ##p<0.01 comparing within the group. 
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in animals with 25 and 53 weeks of diet, respectively. CSN resection decreased lipid 
deposition in the liver in all groups of animals, an effect that was statistical significant 
in control (21.46% decrease) and aged (35.28% decrease) animals submitted to 
hypercaloric diets (Figure 4.5.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Figure 4.6. shows the effect of long-term hypercaloric diet intake and the effect of the 
chronic CSN resection on the liver´s TG content in young and old animals. Ageing 
increased by 65.52% the TG accumulation in the liver, an effect that decreases in a non-
significant manner with CSN resection. Hypercaloric diet consumption in young 
animals did not modify TG content in the liver, however age combined with the long-
term hypercaloric consumption increased levels by 402.15%, an effect that was almost 
totally reversed with the CSN resection (57.13% decrease) (Figure 4.6.). 
 
 
 
25 weeks                53 weeks 
Figure 4. 5. Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on the level of total lipids content within the liver of young and old 
animals. White bars represent the values of animals without CSN resection, black bars 
represent the values of animals with CSN resection. Bars represent mean±SEM of 4-6 values. 
One- and Two-Way ANOVA with Bonferroni multicomparison tests; *p<0.05 vs CTL 25 
weeks; ##p<0.01 and ###p<0.001 comparing within the group and §§p<0.01 and 
§§§§p<0.0001 comparing with controls with the same age. 
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4.8.  Effect of long-term hypercaloric diet intake and carotid sinus 
nerve resection on hepatocellular changes in young old animals 
 
   Figure 4.7. depicts the effect of HFHSu diet, age and CSN resection on the 
macroscopic appearance of the liver. Liver images taken post mortem show an increase 
in lipid droplets with the intake of 25 and 53 weeks of HFHSu diet. Ageing also impacts 
lipid deposition within the liver, since older rats visually exhibit an increase in the lipid 
droplets. Ageing plus hypercaloric diet exacerbated lipid deposition in the liver. While, 
it was not possible to show the effects of the CSN resection in the young group, CSN 
denervation in HFHSu animals of 53 weeks clearly improved lipid deposition in the 
liver.  
25 weeks                53 weeks 
Figure 4. 6.  Effect of long-term hypercaloric diet consumption and of carotid sinus nerve 
(CSN) resection on triglycerides levels within the liver of young and old animals. White 
bars represent the values of animals without CSN resection, black bars represent the values of 
animals with CSN resection. Bars represent mean±SEM of 5 values. One- and Two-Way 
ANOVA with Bonferroni multicomparison tests; *p<0.05 and ****p<0.0001 vs CTL 25 weeks; 
##p<0.01 vs HFHSu 25 weeks; §§§p<0.001 comparing with controls with the same age and 
£p<0.05 comparing within the group. 
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Figure 4. 7. Macroscopic images of the effect of long-term hypercaloric diet consumption  
and of carotid sinus nerve (CSN) resection in the liver of young and old animals. 
 
 
 
 
 
 
 
 
   To confirm the macroscopic data, a microscopic analysis of the livers was performed. 
H&E staining of the livers  (Figure 4.8.) depict clear steatosis in animals submitted to 
the hypercaloric diet during 25 and 53 weeks. This steatosis was showed by marked 
liver micro and macrovesicular hepatocellular vacuolization. CSN resection improved 
these liver fatty changes both in young and old animals submitted to the HFHSu diet 
(Fig. 4.8). Age per se did not seem to alter significant lipid deposition as well as CSN 
denervation in control and aged animals fed with standard diet.  
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Figure 4. 8. Hematoxylin and Eosin (H&E) staining displaying the effect of long-term 
hypercaloric diet intake and the effect of chronic carotid sinus nerve (CSN) resection on 
the liver of young and old rats. Rats on HFHSu diet show marked hepatocellular 
vacuolization, micro and macrovesicular, which is reverted with CSN resection. Scale bar, 100 
μm; original magnification 20x. Black arrowhead: fatty change (lipidosis); white arrowhead: 
fibrosis. 
 
   Figure 4.9. details the hepatocellular score analysis from the H&E staining displaying 
the effects of long-term hypercaloric diet intake and the effect of the chronic CSN 
resection on young and old animals. From the fatty change score (Figure 4.9. A) it was 
possible to observe an increase in tissue steatosis with diet consumption , an effect that 
was exacerbated in old animals. Also, CSN resection decreased fatty accumulation in 
HFHSu animals, this reaching statistical significance in old animals. Hepatocellular 
damage (Figure 4.9. B) increased in young HFHSu animals and in aged animals, these 
values reaching only significance in the old group. Note that CSN resection ameliorated 
or even reversed hepatocellular damage within these groups, respectively. Liver 
inflammation score (Figure 4.9. C) increased in young animals submitted to 
hypercaloric diet and in aged animals and CSN resection reversed these effects.  In 
concordance with the inflammation score, the fibrosis score (Figure 4.9. D) increased in 
young animals submitted to hypercaloric diet and in aged animals, effects that were 
reduced with CSN resection. 
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Figure 4. 9. Effect of long-term hypercaloric diet and of carotid sinus nerve (CSN) 
resection on the hepatocellular scores of young and old animals: fatty change (A), 
hepatocellular damage (B), inflammation (C)and fibrosis (D). White bars represent 
the values of animals without CSN resection, black bars represent the values of animals 
with CSN resection. Bars represent mean±SEM of 4-5 values. One- and Two-Way 
ANOVA with Bonferroni multicomparison tests; *p<0.05, **p<0.01 and ****p<0.0001 
vs CTL 25 weeks; #p<0.05 and ##p<0.01 comparing within the group and §§§§p<0.0001 
comparing with controls with the same age. 
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5. Discussion and Conclusions 
 
   In this study, it was demonstrated that long-term hypercaloric consumption did not 
modify age-induced insulin resistance, while exacerbates glucose intolerance. It was 
also observed that the chronic bilateral CSN resection in old animals restored insulin 
sensitivity and glucose tolerance. Age and the HFHSu consumption increased plasma 
TG, an effect that was restored by the CSN resection. In the liver, the lipid content and 
the TG increased with the HFHSu diet and with age, being exacerbated by the long-
term HFHSu consumption. Moreover, the CSN ameliorates theses alterations in the 
liver. We conclude that the CSN resection was able to restore insulin sensitivity and 
glucose tolerance and ameliorate liver steatosis induced by age and exacerbated by 
hypercaloric diet. 
   Age and the long-term HFHSu consumption did not modified the fasting glucose 
levels, an effect that was not altered by the CSN resection. These results are in 
accordance with previous works from Escrivá et al (2007). and Guarino et al, (2013) 
that did not observed changes in fasting glucose levels in Wistar rats with 3, 8, 12 and 
24 months fed with a standard diet (Escrivá et al., 2007; Guarino et al., 2013). Also, 
Sacramento et al. did not described differences in the fasting glucose levels of CTL 
animals with 25 weeks of diet (Sacramento et al., 2018). Shimokata et al. showed in an 
human cohort study that age leads to an increase in the fasting glucose levels and aging 
men tend to have higher levels than women (Shimokata et al., 1991). Even though the 
fasting glucose remain unmodified with the long-term hypercaloric diet this effect was 
not observed in young animal models submitted to different hypercaloric diets. Melo et 
al. compared several groups of rats submitted to different types of hypercaloric diets for 
different periods of time: high-fat (HF) diets for 3 and 19 weeks, high-sucrose (HSu) 
diets for 4 and 16 weeks and with HFHSu diet for 25 weeks (Melo et al., 2019) and 
demonstrated that all groups of animals increased their fasting glucose levels except the 
16 weeks HSu animals (Melo et al., 2019). The 3 weeks HF had an increase of 15%, the 
HF 19 weeks of 13%, HSu 4 weeks of 25% and HFHSu 25 weeks of 154% (Melo et al., 
2019). Even though fasting glucose levels increased in these animal models none of 
them reached values above 126 mg/dl, the reference value for T2D diagnosis. Chalkley 
et al. demonstrated in 2 months old Wistar rats fed for 9-10 months with HF diet that 
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there is an increase in the fasting glucose levels (Chalkley et al., 2002). Kawasaki et al. 
showed in Wistar-Imamichi rats fed with Hsu diets for a total of 36 weeks and observed 
no difference in fasting glucose levels at 8, 12 and 24 weeks (Kawasaki et al., 2005). 
However, after 28 and 36 weeks of HSu diet was observed an increase in fasting 
glycemia (Kawasaki et al., 2005).  Additionally, Sacramento et al. demonstrated that 
the increase in fasting glucose levels experienced by the 25 weeks HFHSu diet rats was 
reversed by the CSN resection (Sacramento et al., 2018). Although, the increase in 
fasting glucose levels seen with the hypercaloric diets (HSu, HF and HFHSu) is 
extensively accepted, this effect was not seen in the animals submitted to 53 weeks of 
diet (Kamgang et al., 2005; Wilson and Hughes 1996; Ribeiro et al., 2005; Ebaidet al., 
2006, Melo et al. 2019).  
   Age decreased insulin sensitivity, but the long-term HFHSu diet consumption did not 
intensify the age-induced insulin resistance. The decrease in the insulin sensitivity and 
the consequent peripheral insulin resistance with age, it is widely accepted as a 
consequence of age both in humans and animals (DeFronzo, 1981; Escrivá et al., 2007; 
Fink et al., 1983) . Additionally, Guarino et al. has also showed in rats with 3, 12 and 
24 months increase insulin resistance with age (Guarino et al., 2013). Knowing that age 
itself bring the drawback of insulin resistance both in animals and humans, it is of 
pivotal importance a way of oppose this tendency (DeFronzo, 1981; Escrivá et al., 
2007; Fink et al., 1983).  
   Over the last years, it was demonstrated that the resection or the bioelectronic 
modulation of the CSN activity in young animal models of prediabetes and in an early-
stage of T2D were able to prevent and reverse the insulin resistance and the glucose 
intolerance (Ribeiro et al., 2013; Sacramento et al., 2017, 2018). Knowing the social 
reality of an aging society, in the present work we tested the effect of CSN resection in 
old animals, as proof of principle that CSN/CB modulation might be a feasible 
therapeutic for these pathologies. We demonstrated for the first time that the CSN 
resection in aged CTL rats reverts the effects of aging on insulin sensitivity, an effect 
that was completely reversed at 4 weeks after the CSN resection. The denervation also 
reverted the insulin resistance in aged HFHSu (53 weeks of diet) animals, an effect that 
was achieved 2 weeks after the CSN resection, which counteracts the nefarious effects 
of the age and the HFHSu diet on their insulin sensitivity. CSN resection was also able 
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to restore insulin sensitivity in old animals. The increase in the SNS activity was 
proposed to be the link between the CB and the development of insulin resistance in 
young animals (Ribeiro et al., 2013). Although in this work the SNS activity was not 
assessed, it has already been documented the deregulation of the SNS in older people 
(Esler et al., 1995; Rowe and Troen, 1980).  
   One of the stepping points to the genesis of glucose intolerance is an already 
established insulin resistance. From the AUC of the OGTT it was observed that 
intolerant to glucose with 44 weeks of HFHSu diet, but the impact of age alone did not 
affect the glucose tolerance. Sacramento et al. showed that there is no alteration on the 
glucose tolerance in CTL rats with 25 weeks diet, however as expected animals fed with 
an HFHSu diet for a period of 25 weeks developed glucose intolerance. Therefore, the 
HFHSu diet consumption during 25 and 53 weeks have an impact on the glucose 
tolerance, which did not happen in the CTL animals, meaning that the caloric intake of 
the diets has a major role in the dysfunction of the glucose homeostasis. Other authors 
had also observed that the HF consumption during 14 and 17 weeks induced glucose 
intolerance in Wistar rats, in Sprague-Dawley rats and mice (Akiyama et al., 1996; 
Marques et al., 2016; Nascimento et al., 2008; Winzell and Ahrén, 2004). Even though 
age did not alter the glucose tolerance in the CTL rats (13 months old), Wang et al. 
described in 22 months old Wistar rats a decrease in the tolerance to glucose and that 
the rats became glucose intolerant with age (Wang et al., 1997). In this study, 13 
months of age was enough to induce insulin resistance but not to induce glucose 
intolerance, meaning that probably if we increase the time of our experiments the 
animals might develop glucose intolerance (Wang et al., 1997). Also, it is know that in 
humans an impaired glucose tolerance tends to develop with age (DeFronzo, 1981; 
Jackson, 1990). Yet, Reaven et al. made a great argument whether or not this age-
related glucose intolerance seen in humans was a result of age per se or a secondary 
effect to other various age-related variables, as chronic diseases, medication and 
physically less active (Reaven and Reaven, 1985). So, it might be possible that some 
proportion of the decline in glucose tolerance may be independent of age in itself 
(Reaven and Reaven, 1985).    
   Furthermore, the old rats that became glucose intolerant with the HFHSu diet reverted 
this intolerance with the CSN resection. Therefore, the denervation of the CSN is not 
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only able to reverse the insulin resistance but also the glucose intolerance in old 
animals. This effect was also seen in the 25 week HFHSu diet animals, where the CSN 
resection and the bioelectronics modulation of the CSN activity was capable of 
reverting the glucose intolerance (Sacramento et al., 2018). By comparing the previous 
results between 25 and 53 week HFHSu diet and the link between the SNS, the CB and 
the insulin resistance, a pattern for a possible therapy starts to arise, with the modulation 
of the CB or the CSN activity being a key part of it. 
   Herein, this work also showed that a long-term hypercaloric diet increases weight 
gain, as well as an increase in the rat’ total fat depots: perienteric, perinephric and 
epididymal fat. 
   As expected caloric intake increases body weight, both in CTL animals fed a diet of 
2.56 Kcal/g and in HFHSu 5.10 Kcal/g of high-fat diet plus 1.36 Kcal/g of high-sucrose. 
Even though the HFHSu animals were fed a much caloric diet there is only a slight 
increase in body weight. The animals may consume more calories but may burn more, 
as this animals might have been more active and spend more calories than the CTL. 
Also, the surgeries, sham and CSN resection, provoked a decrease in body weight. The 
decrease with the CSN resection is more pronounced than with the sham, so the 
decrease might not only be because of the surgery per se but also an effect of the CSN 
denervation. In animal studies has been sowed the increase of weight with an HF diet 
and a significant decrease with the CSN resection(Ribeiro et al., 2013). 
   Age increased total fat in control animals when compared with animals submitted to 
25 weeks of standard diet (Sacramento et al., 2018), being this increase due to an 
augment in the perinephric and perienteric fat. CSN resection did not alter fat content in 
control old animals as it occurred in young control animals (25 weeks of diet) 
(Sacramento et al., 2018). The increase in fat it is clearly marked with the 53 weeks of 
HFHSu diet. Sacramento et al. showed an increase in the fat depots HFHSu animals 
submitted to 25 weeks of diet. Even though, Sacramento et al. observed a decrease in 
the perinephric fat with the CSN resection, the old animals did not show a decrease in 
any of the fat depots with the CSN resection. One possible explanation is that the 
amount accumulated during the 53 weeks on hypercaloric diet requires more time to 
have an effect than a period of nine weeks after the denervation. A similar situation 
might occur on the 25 weeks of diet animals where eleven weeks of follow-up it is not 
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enough to see marked changes in the fat depots. Moreover, the increase in fat content 
described with the hypercaloric diet brings some health complications, like obesity and 
dyslipidemia and aggravates the insulin resistance (Kim et al., 2000). There is a 
correlation between the decrease in insulin sensitivity and the increase in body fat 
deposition in animals as well as in humans (Carey et al., 1996; Kim et al., 2000). In rats 
and mice fed with a HF diet it was observed an increase in visceral fat accumulation, 
whole body and muscle insulin resistance and hyperinsulinemia within 4 week (Han et 
al., 1997; Kim et al., 2000; Kraegen et al., 1986; Zierath et al., 1997) . Additionally, if 
the HF diet continues for a long period of time (8 months), rats and mice develop severe 
visceral obesity and diabetes or impaired glucose tolerance (Han et al., 1997; Kim et al., 
2000). Therefore, the increase in fat depots may influence the decrease in insulin 
sensitivity seen in the old and young animals. 
   Total cholesterol levels in plasma did not change significantly with age.  It was 
previously described that cholesterol levels tend to increase with age both in humans 
and animals (Uchida et al., 1978). Uchida et al. demonstrated that serum and liver lipid 
levels increase with age in both Sprague-Dawley and Wistar rats (Uchida et al., 1978). 
Also, plasma levels of total and LDL-cholesterol are well known to increase with aging 
(Uranga and Keller, 2010). This might be a casual factor of the decrease in the plasma 
clearance of LDL in  humans and rodents, the decreased breakdown of cholesterol to 
bile acids in aging rodents, as well as the increased intestinal cholesterol absorption in 
aging mice and rats (Ericsson et al., 1991; Uranga and Keller, 2010; Wang, 2002). 
Additionally, total cholesterol increased in old HFHSu animals, an effect that was not 
observed in young HFHSu animals, which leads to the conclusion that the increase 
observed in old animals is a result of the long-term hypercaloric intake. The 
hypercaloric diets consumption specially during a prolonged period tends to increase 
plasma total cholesterol levels in rats, since the caloric intake effects poorly the lipid 
profile (Uranga and Keller, 2010).  
   The effects of HF diets on cholesterol metabolism have been studied in both humans 
and animals, and it have been associated with hyperlipidemia (Uranga and Keller, 
2010). Studies in humans have shown that Western diets consumption induced an 
increase in both total and LDL cholesterol levels in plasma and a significant reduction 
in HDL cholesterol (Uranga and Keller, 2010) . When people consume a balanced diet 
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and low in fat exhibit low total cholesterol and low LDL cholesterol levels (McMurry et 
al., 1991; Uranga and Keller, 2010). However, when these people are placed on more 
typical Western diets, their total and LDL cholesterol levels increase (McMurry et al., 
1991; Uranga and Keller, 2010).  
   In this study, it was observed an increase in TG levels in control old animals. The 
increase in TG with age is not consensual in the literature. Mesomya et al. showed in 
Sprague – Dawley rats of 4, 8 and 12 months an irregular variation of TG levels with 
age, since the levels of TG increased from 4 to 8 months but decreased from 8 to 12 
months (Mesomya et al., 2001). However, high TG levels have been demonstrated in 
aged rats (Jayachandran et al., 1996). In relation to human data, a study by Puga et al. 
was unable to find changes in TG levels between young and old people (Puga et al., 
2011) but Cassader et al. showed that older people have higher TG levels (Cassader et 
al., 1996).  
   In the present thesis, TG levels in old HFHSu animals were similar than TG levels in 
young HFHSu animals, suggesting that long-term hypercaloric diet did not exacerbate 
the increase in TG levels that it is established with 25 weeks of hypercaloric diet. The 
absence of statistical significance in the old animals might be due to the reduced 
number of samples (n=4). Although our results are in agreement with the literature: Yan 
et al. described in Wistar rats fed for 20 weeks with HF diet an increase in the TG 
plasma levels (Yan et al., 2006) and Melo et al. also demonstrated the increase the 
triglycerides levels in HF 3 weeks, HF 19 weeks, Hsu 4 weeks, HSu 16 weeks and 
HFHSu 25 weeks of diet animals (Melo et al., 2019). CSN resection in 25 and 53 week 
HFHSu rats significantly impact TG levels, as the values were significantly reduced, 
elucidating once more the beneficial effects of CB activity ablation.  
   Metabolic diseases are connected to each other, through the disturbance of lipids in 
the body and insulin resistance (Blaton, Korita and Bulo, 2008; Katsiki, Mikhailidis and 
Mantzoros, 2016; Klop, Elte and Cabezas, 2013; Mooradian, 2009). Since, insulin 
resistance influences the increase in FFA and the deregulation of the lipid metabolism 
in the liver and adipose tissue (Katsiki, Mikhailidis and Mantzoros, 2016), and  
knowing from the already discussed results of the effect of the CSN denervation on the 
insulin resistance, it is plausible that the CSN resection impacts the rats lipid profile 
through the improvement on insulin sensitivity.  
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  The liver is one of the central organs in metabolic diseases and therefore  the present 
study aimed to elucidate the effects of the age and long-term HFHSu diet and the CSN 
resection on the liver dysfunction of young and old animals. A macroscopic evaluation 
of the livers at a terminal experiment, showed a slight increase in lipidic droplets in 
aged animals and in animals submitted to hypercalorioc diet and an exacerbated effect 
when diet is combined with age . Even though there is no visual record of the effect of 
the CSN resection on the liver of young HFHSu animals, the liver from HFHSu old 
animals submitted to the CSN resection showed a high reduction in these lipidic 
droplets.  
 The total lipid and TG content in the liver as evaluated to confirm the macroscopic 
results. From this analysis, it was possible to observe an increase in the total lipid 
content with the age and with the hypercaloric diet in both young and old groups. The 
TG content increased with age and the long-term HFHSu diet. Both in rats and humans 
age leads to an increase in the lipids accumulation in the liver (Castro, de et al., 2013; 
Kuk et al., 2009). Age can also create dysfunctions in the lipid and glucose metabolism 
(Guarino et al., 2013; Uchida et al., 1978). Moreover, the increase in the total lipid 
content and TG was higher in the animals submitted to the long-term HFHSu diet. As, 
Westerbacka et al. demonstrated in humans, the type of diet has a key role in the lipid 
accumulation in the liver, since liver fat decrease during consumption of low-fat diet 
and increase with HF diet (Westerbacka et al., 2005). Knowing that hypercaloric diet 
leads to an increase in the lipid profile, which is deeply connected to insulin resistance 
and metabolic diseases, this can bring considerable consequences for the liver(Taskinen, 
2005; Uranga and Keller, 2010; Yan et al., 2006). Moreover, since a dysfunction in 
glucose homeostasis and dyslipidemia can create a flow of FFA into the liver, these 
dysfunctions induced by the hypercaloric diets or aging might lead to the eventual 
hepato-steatosis (Vanni et al., 2010).  
   An impaired glucose uptake by the muscle and an inadequate insulin suppression of 
lipolysis in the adipose tissue, together with the liver´s overproduction of glucose, 
despite fasting hyperinsulinemia, contribute greatly to the increase of fat deposition in 
the liver and may be the reason behind the increase of total lipid content in the liver and 
of the increase in lipidic droplets observed both, macroscopic and microscopically in 
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liver images (Vanni et al., 2010; Yki-Järvinen, 1993). Being the lipolysis the main 
source of hepatic TG in NAFLD, an peripheral insulin resistance would result in the 
increase of the TG deposition in the liver, as seen in the old animals (Vanni et al., 2010; 
Yki-Järvinen, 1993). Studies have suggested that increased delivery of FFA into the 
liver is associated with increase of liver fat content, as the one observed in the old 
animals(Taskinen, 2005). The increase in lipid accumulation in the liver leads to the 
hepato-steatosis seen metabolic diseases like NAFLD, which can then evolve into 
NASH (Bugianesi et al., 2005; Seppälä-Lindroos et al., 2002).  
   Herein we found that CSN resection not only improved the overall body glucose 
metabolism but also improve dysfunction (adipose tissue, muscle and liver) and impairs 
normal metabolic processes (glucose uptake, lipolysis and hepatic de novo lipogenesis 
inhibition) (Bajaj and DeFronzo, 2003; Boden and Chen, 1995; Kashyap et al., 2003). 
So, by restoring insulin sensitivity the overall improvement can lead to the 
hepatocellular restoration. The reduction of the lipid accumulation with the CSN 
resection might be an indirect effect, due to the restoration of insulin sensitivity or 
might be a more direct effect on the liver. In order to elucidate this further studies are 
required.   
   Confirming our macroscopic and biochemical alterations in the liver, the microscopic 
H&E staining analysis of the liver showed slight differences with age. As expected, an 
increase in the lipidosis was observed in both young and old animals fed with 
hypercaloric diets and a decrease, as seen earlier, with the CSN resection. Aging is 
associated with a physiological increase in lipid accumulation in the liver and with an 
increased prevalence of NAFLD in aged humans(Sheedfar et al., 2013). Due to an 
increase in hypercaloric food availability and consumption the prevalence of NAFLD 
has increase (Alwahsh and Gebhardt, 2017). The hepatocellular scores were performed 
in order to accessed if the effects of the hypercaloric diet and the age were able to 
induce other NAFLD characteristics. According to the “two-hits” model for the 
progression of liver damage, the “first hit” is marked by a reversible deposition of lipids 
in the liver, and the “second hit” by irreversible hepatocyte injury, like lipid 
peroxidation, induction of inflammatory cells and fibrogenesis with extracellular matrix 
deposition(Vanni et al., 2010). Clearly, the animal model studied in the present work 
was capable of mimic the “first hit” of NAFLD with the deposition of lipids in the liver. 
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When the livers were analyzed for the fatty change score, to evaluate the “first-hit” of 
NAFLD, no differences were found with age, but it was observed an increase in lipids 
accumulation with HFHSu diets in both young and old groups and a decrease with the 
CSN denervation in the HFHSu old animals, confirming the macroscopic images and 
the liver lipid content. The hepatocellular damage score evaluates the potential tissue 
hyperplasia or hypertrophy, which are major contributors of the progression from 
NAFLD to NASH, and therefore  the “second hit” of NAFLD. In the present work, we 
observed an increase in the hepatocellular damage with age and HFHSu diet (25 weeks) 
but not with the long-term hypercaloric diet. These results were quite surprisingly, but 
can anticipate a possible compensation to avoid major liver dysfunction. CSN resection 
was able to reduce the cellular damage in the liver of old control animals. Tissue 
inflammation is a step forward on the progression of the NAFLD that drives the 
transition from benign steatosis toward more advanced NASH(Sheedfar et al., 2013). 
Livers were analyzed for the liver’s inflammation score and it was possible to observe 
an increase with age and with the 25 weeks hypercaloric diet, effects that were restored 
by the CSN denervation. Fibrosis is seen as a defining characteristic of the NASH and 
represents an irreversible evolution of the pathology (Vanni et al., 2010). The fibrosis 
score showed an increase with age and with the hypercaloric diet, an effect that was 
reverted with the CSN resection.  
   All these results combined lead us to believe that this model is capable of simulating 
the disease steps in humans. The early stage of the disease is marked by an increasing 
lipidosis in the liver, as showed in the livers of the 25 weeks HFHSu diet rats. 
Importantly, this model not only shows the early stage of the disease but also a 
progression, observed by the hepatocellular damage and tissue inflammation, into a 
more severe stage of the disease. Herein, some old animals and some animals submitted 
to 25 weeks of HFHSu diet start to show also evidences of the late stage of NAFLD, 
NASH, which is deeply marked with tissue fibrosis and with considered irreversible 
damage (Vanni et al., 2010).  
   Moreover, these results showed that the ablation of the activity of the CB/CSN has a 
great potential to treat NAFLD and even NASH, two disorders that lack therapeutic 
strategies, and which the usual outcome is the liver transplant (Vanni et al., 2010). So, 
further investigation is required to elucidate the link between the CB, SNS, insulin 
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resistance and metabolic disturbances, like NAFLD and to understand if the effects seen 
in this work are from a direct modulation on the CB into the organ and/or a result of an 
indirect approach.  
 
   In conclusion, in an aged world with increasingly incidence of metabolic diseases and 
where disorders like MS, NAFLD, T2D and prediabetes are seen as a growing epidemic 
it is of outmost importance to find a way to stop these disorders. Only with an efficient 
therapy we can oppose this public health issue. With the study of the mechanisms 
behind these comorbidities we might uncover an approach to stop the pathological 
vicious cycle. The present study, demonstrates that the abolishment of the CB/CSN 
activity in old rats can restore insulin sensitivity, glucose tolerance and have significant 
impact on the liver of these animals. Our results suggest that the modulation of CB 
activity might be important in age-induced metabolic dysfunction and metabolic 
dysfunction exacerbated by hypercaloric diet consumption, but also in liver-associated 
metabolic dysfunctions in young and old animals. So, this work might have shed some 
light on a possible therapeutic strategy with the modulation of the CB or the CSN 
activity to not only treat but also to prevent these age-associated disorders. 
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